Anticholinergics

JP2023550798A5Active Publication Date: 2024-11-28REZUBIO PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532105
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-26
Filing Date
2021-11-24
Publication Date
2024-11-28
Estimated Expiration
2041-11-24

AI Technical Summary

Technical Problem

There is a need for new muscarinic acetylcholine receptor antagonists to treat various indications, as existing anticholinergic drugs are insufficient for diverse medical conditions.

Method used

Development of novel compounds and their pharmaceutically acceptable salts, which act as muscarinic acetylcholine receptor antagonists, specifically targeting M3 receptors, and are formulated into pharmaceutical compositions for various routes of administration to treat conditions like hyperhidrosis and other disorders.

Benefits of technology

The compounds effectively inhibit M3 muscarinic acetylcholine receptors, providing therapeutic benefits for conditions such as hyperhidrosis, peptic ulcers, drooling, gastric and respiratory secretions, heart protection, and chronic obstructive pulmonary disease, among others, through targeted anticholinergic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022111500000001
    Figure 2022111500000001
  • Figure 2022111500000002
    Figure 2022111500000002
  • Figure 2022111500000003
    Figure 2022111500000003
Patent Text Reader

Abstract

Provided are compounds of formula (I), pharmaceutical compositions, and methods of use relating to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M3 antagonists, that can be used to treat a variety of disorders, conditions, or diseases, such as hyperhidrosis. JPEG2023550798000065.jpg47170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure generally relates to novel compounds, pharmaceutical compositions, methods for preparing them, and methods for using them, in various embodiments, for providing anticholinergic effects, etc. [Background technology]

[0002] Muscarinic acetylcholine receptors, or mAChRs, are acetylcholine receptors that form G protein-coupled receptor complexes on the cell membrane. Five subtypes of muscarinic receptors have been identified and are designated M1-M5. M1, M3, and M5 receptors are G q The M2 and M4 receptors bind to proteins, and G i / o They bind to proteins. mAChRs are widely expressed in different tissues and cells and regulate many important functions of the central and peripheral nervous systems. In the bladder, M2 and M3 receptors are mainly expressed in the detrusor muscle of various species. Both M1 and M3 receptors are expressed in the salivary glands, sweat glands, apocrine glands, sublingual glands, and lacrimal glands, but the M3 receptor is mainly expressed in the parotid gland. In the gastrointestinal tract, both M2 and M3 receptors are expressed in smooth muscle, and the M3 receptor is thought to play an important role in the cholinergic stimulation of gastrointestinal motility. In the brain, the M3 receptor is low in expression, while the M1, M2, M4, and M5 receptors are abundantly expressed in different regions. M1 and M4 receptors are expressed in the human eye. M2 and M3 receptors are expressed in the human heart and regulate heart rate and cardiac function. Muscarinic anticholinergics are used to treat a variety of diseases or disorders, including diarrhea, allergies, asthma, atrial fibrillation with bradycardia, motion sickness, anxiety, hyperhidrosis, low heart rate, overactive bladder, respiratory diseases such as asthma and COPD, and neurological diseases such as Parkinson's disease and Alzheimer's disease.

[0003] Various muscarinic acetylcholine receptor antagonists have been reported, including naturally occurring atropine and scopolamine, as well as various synthetic drugs such as homatropin and eucatropin. However, there is still a need for new muscarinic antagonists for a variety of indications.

Summary of the Invention

[0004] The present disclosure is based on novel compounds / salts that can provide an anticholinergic effect, more specifically, an action as a muscarinic acetylcholine receptor antagonist, in various embodiments.

[0005] Some embodiments of the present disclosure are directed to salts of formula I, JPEG2023550798000002.jpg63170wherein the variables R 1 、R 2 、R 3 、R 4 、L 1 、X - 、and j are defined herein. In some embodiments, the present disclosure provides salts of sub-formulas of formula I such as formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6 described herein. The salts of formula I herein are typically muscarinic receptor antagonists. The salts of formula I can typically be prepared from the corresponding compounds of formula II, JPEG2023550798000003.jpg38170wherein the variables R 1 、R 2 、R 3 、L 1 、and j are defined herein. In some embodiments, the present disclosure also provides pharmaceutically acceptable salts of compounds of formula II (e.g., formula II-1 or II-2).

[0006] Certain embodiments of this disclosure relate to pharmaceutical compositions comprising one or more compounds / salts of the disclosure (e.g., compounds / salts of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, or pharmaceutically acceptable salts thereof), and optionally pharmaceutically acceptable excipients. Pharmaceutical compositions described herein can be formulated for different routes of administration, such as oral administration, parenteral administration, topical administration, inhalation, and ophthalmic administration. For example, in some embodiments, the pharmaceutical composition may be prepared for topical administration in the form of a topical solution, cream, ointment, mousse, gel, lotion, or powder.

[0007] Some embodiments of this disclosure relate to methods for treating or preventing disorders, conditions, or diseases that may respond to antagonism of mAChRs, such as M3 receptors, in subjects requiring such treatment or prevention. In some embodiments, the method involves administering an effective amount of a compound of this disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, or any pharmaceutically acceptable salt thereof) or an effective amount of a pharmaceutical composition described herein to a subject.

[0008] Some embodiments of this disclosure relate to methods for inhibiting the activity of mAChRs, such as M3 receptors, in a subject or biological sample. In some embodiments, the method involves contacting mAChRs, such as M3 receptors, with an effective amount of a compound of this disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein.

[0009] In some specific embodiments, the Disclosure provides a method for treating hyperhidrosis in a subject requiring such treatment. In some embodiments, the method involves administering a therapeutically effective amount of a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) to a subject. Typically, administration is carried out via a topical route. In some embodiments, one or more compounds / salts of the present disclosure may be administered as the sole active ingredient. In some embodiments, one or more compounds of the present disclosure may be used in combination with additional therapies, for example, additional therapies effective in treating hyperhidrosis.

[0010] Please understand that the above summary of the invention and the following detailed description are merely illustrative and descriptive, and do not limit the invention described herein. [Modes for carrying out the invention]

[0011] This disclosure relates to compounds that are generally useful as muscarinic anticholinergic agents. The compounds herein can typically be used to treat or prevent a variety of diseases or disorders mediated by such muscarinic cholinergic receptors as described herein, such as those mediated by M3 receptors.

[0012] compound Equation I In some embodiments, the present disclosure provides salts of formula I, JPEG2023550798000004.jpg48170In formula, X - It is a counterion, R 1 is hydrogen, or optionally substituted C 3-8 It is carbocyclyl. L 1 is empty (null), C 1-4 Alkylene, or C 1-4 It is a heteroalkylene, R 2 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Carbocyclyl, a 4-8 membered heterocyclyl, phenyl, or a 5-10 membered heteroallyl, each of which can be optionally substituted. R 3 and R 4 Each of them independently consists of hydrogen or C 1-6 It is alkyl, j is 0, 1, or 2.

[0013] In some embodiments, salts of formula I (including any of the applicable sub-formulas described herein) may contain one or more asymmetric centers and / or axial chiralities, and thus may exist in various stereoisomer forms, e.g., enantiomers and / or diastereomers. In some embodiments, salts of formula I may exist, where applicable, in the form of individual enantiomers and / or diastereomers, or in the form of a mixture of stereoisomers including a racemic mixture and a mixture rich in one or more stereoisomers. In some embodiments, where applicable, salts of formula I (including any of the applicable sub-formulas described herein) may exist as isolated individual enantiomers substantially free of other enantiomers (e.g., in amounts less than 20%, less than 10%, less than 5%, less than 1%, or undetectable amounts, by weight, HPLC area, or both). In some embodiments, where applicable, salts of formula I (including any of the applicable sub-formulas described herein) may exist as isolated individual diastereomers substantially free of other diastereomers (e.g., in amounts less than 20%, less than 10%, less than 5%, less than 1%, or undetectable, by weight, HPLC area, or both). In some embodiments, where applicable, salts of formula I (including any of the applicable sub-formulas described herein) may also exist as a mixture of stereoisomers in any proportion, such as a racemic mixture.

[0014] In some embodiments, the salt of formula I may have formula I-1: In formula JPEG2023550798000005.jpg47170, the variables include any combination of any of those described herein.

[0015] In some embodiments, the salt of formula I-1 may have formula I-1-E1 or formula I-1-E2. JPEG2023550798000006.jpg46170

[0016] In some embodiments, the salt of formula I-1 may have formula I-1-E3 or formula I-1-E4. JPEG2023550798000007.jpg46170

[0017] In some embodiments, the salt of formula I-1 may be a substantially pure stereoisomer having formula I-1-E1 and may substantially not contain any of the corresponding isomer forms of formulas I-1-E2, I-1-E3, and I-1-E4. For example, in some embodiments, the total amount of formulas I-1-E2, I-1-E3, and I-1-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-1-E2, I-1-E3, and I-1-E4 are detectable. In some embodiments, the salt of formula I-1 may be a substantially pure stereoisomer having formula I-1-E2 and may substantially not contain any of the corresponding isomer forms of formulas I-1-E1, I-1-E3, and I-1-E4. For example, in some embodiments, the total amount of formulas I-1-E1, I-1-E3, and I-1-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-1-E1, I-1-E3, and I-1-E4 are detectable. In some embodiments, the salt of formula I-1 may be a substantially pure stereoisomer having formula I-1-E3, and may substantially not contain any of the corresponding isomer forms of formulas I-1-E1, I-1-E2, and I-1-E4. For example, in some embodiments, the total amount of formulas I-1-E1, I-1-E2, and I-1-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-1-E1, I-1-E2, and I-1-E4 are detectable. In some embodiments, the salt of formula I-1 may be a substantially pure stereoisomer having formula I-1-E4 and may substantially not contain any of the corresponding isomer forms of formulas I-1-E1, I-1-E2, and I-1-E3.For example, in some embodiments, the total amount of formulas I-1-E1, I-1-E2, and I-1-E3 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1%, respectively, by weight, by HPLC area, or both, or none of formulas I-1-E1, I-1-E2, and I-1-E3 are detectable. In some embodiments, a given salt of formula I-1 can exist in the form of a mixture of any two or more of the four possible stereoisomers, formulas I-1-E1, I-1-E2, I-1-E3, and I-1-E4, in any ratio.

[0018] In some embodiments, the salt of formula I may have formula I-2: In formula JPEG2023550798000008.jpg56170, the variables include any combination of any of those described herein.

[0019] In some embodiments, the salt of formula I-2 may have formula I-2-E1 or formula I-2-E2. JPEG2023550798000009.jpg50170

[0020] In some embodiments, the salt of formula I-2 may have formula I-2-E3 or formula I-2-E4. JPEG2023550798000010.jpg49170

[0021] In some embodiments, the salt of formula I-2 may be a substantially pure stereoisomer having formula I-2-E1 and may substantially not contain any of the corresponding isomer forms of formula I-2-E2, I-2-E3, and I-2-E4. For example, in some embodiments, the total amount of formulas I-2-E2, I-2-E3, and I-2-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1%, respectively, by weight, by HPLC area, or both, or none of formulas I-2-E2, I-2-E3, and I-2-E4 are detectable. In some embodiments, the salt of formula I-2 may be a substantially pure stereoisomer having formula I-2-E2 and may substantially not contain any of the corresponding isomer forms of formula I-2-E1, I-2-E3, and I-2-E4. For example, in some embodiments, the total amount of formulas I-2-E1, I-2-E3, and I-2-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-2-E1, I-2-E3, and I-2-E4 are detectable. In some embodiments, the salt of formula I-2 may be a substantially pure stereoisomer having formula I-2-E3, and may substantially not contain any of the corresponding isomer forms I-2-E1, I-2-E2, and I-2-E4. For example, in some embodiments, the total amount of formulas I-2-E1, I-2-E2, and I-2-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-2-E1, I-2-E2, and I-2-E4 are detectable. In some embodiments, the salt of formula I-2 may be a substantially pure stereoisomer having formula I-2-E4, and may substantially not contain any of the corresponding isomer forms I-2-E1, I-2-E2, and I-2-E3.For example, in some embodiments, the total amount of formulas I-2-E1, I-2-E2, and I-2-E3 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1%, respectively, by weight, by HPLC area, or both, or none of formulas I-2-E1, I-2-E2, and I-2-E3 are detectable. In some embodiments, the salt of formula I-2 can exist in the form of a mixture of any two or more of the four possible stereoisomers, formulas I-2-E1, I-2-E2, I-2-E3, and I-2-E4, in any ratio.

[0022] Typically, in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4), j is 0, 1, or 2. Preferably, in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4), j is 1. For example, in some embodiments, the salt of formula I may be characterized by having formula I-3 or I-4. JPEG2023550798000011.jpg49170

[0023] In some embodiments, the salt of formula I-3 may have formula I-3-E1 or formula I-13-E2. JPEG2023550798000012.jpg45170

[0024] In some embodiments, the salt of formula I-3 may have formula I-3-E3 or formula I-3-E4. JPEG2023550798000013.jpg45170

[0025] In some embodiments, the salt of formula I-3 may be a substantially pure stereoisomer having formula I-3-E1 and may substantially not contain any of the corresponding isomer forms of formula I-3-E2, I-3-E3, and I-3-E4. For example, in some embodiments, the total amount of formula I-3-E2, I-3-E3, and I-3-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formula I-3-E2, I-3-E3, and I-3-E4 are detectable. In some embodiments, the salt of formula I-3 may be a substantially pure stereoisomer having formula I-3-E2 and may substantially not contain any of the corresponding isomer forms of formula I-3-E1, I-3-E3, and I-3-E4. For example, in some embodiments, the total amount of formulas I-3-E1, I-3-E3, and I-3-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-3-E1, I-3-E3, and I-3-E4 are detectable. In some embodiments, the salt of formula I-3 may be a substantially pure stereoisomer having formula I-3-E3, and may substantially not contain any of the corresponding isomer forms I-3-E1, I-3-E2, and I-3-E4. For example, in some embodiments, the total amount of formulas I-3-E1, I-3-E2, and I-3-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-3-E1, I-3-E2, and I-3-E4 are detectable. In some embodiments, the salt of formula I-3 may be a substantially pure stereoisomer having formula I-3-E4, and may substantially not contain any of the corresponding isomer forms I-3-E1, I-3-E2, and I-3-E3.For example, in some embodiments, the total amount of formulas I-3-E1, I-3-E2, and I-3-E3 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1%, respectively, by weight, by HPLC area, or both, or none of formulas I-3-E1, I-3-E2, and I-3-E3 are detectable. In some embodiments, the salt of formula I-3 can exist in the form of a mixture of any two or more of the four possible stereoisomers, formulas I-3-E1, I-3-E2, I-3-E3, and I-3-E4, in any ratio.

[0026] In some embodiments, the salt of formula I-4 may have formula I-4-E1 or formula I-4-E2. JPEG2023550798000014.jpg54170

[0027] In some embodiments, the salt of formula I-4 may have formula I-4-E3 or formula I-4-E4. JPEG2023550798000015.jpg50170

[0028] In some embodiments, the salt of formula I-4 may be a substantially pure stereoisomer having formula I-4-E1 and may substantially not contain any of the corresponding isomer forms of formula I-4-E2, I-4-E3, and I-4-E4. For example, in some embodiments, the total amount of formula I-4-E2, I-4-E3, and I-4-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formula I-4-E2, I-4-E3, and I-4-E4 are detectable. In some embodiments, the salt of formula I-4 may be a substantially pure stereoisomer having formula I-4-E2 and may substantially not contain any of the corresponding isomer forms of formula I-4-E1, I-4-E3, and I-4-E4. For example, in some embodiments, the total amount of formulas I-4-E1, I-4-E3, and I-4-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-4-E1, I-4-E3, and I-4-E4 are detectable. In some embodiments, the salt of formula I-4 may be a substantially pure stereoisomer having formula I-4-E3, and may substantially not contain any of the corresponding isomer forms I-4-E1, I-4-E2, and I-4-E4. For example, in some embodiments, the total amount of formulas I-4-E1, I-4-E2, and I-4-E4 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1% by weight, HPLC area, or both, or none of formulas I-4-E1, I-4-E2, and I-4-E4 are detectable. In some embodiments, the salt of formula I-4 may be a substantially pure stereoisomer having formula I-4-E4, and may substantially not contain any of the corresponding isomer forms I-4-E1, I-4-E2, and I-4-E3.For example, in some embodiments, the total amount of formulas I-4-E1, I-4-E2, and I-4-E3 that may be present among the four possible stereoisomers is less than 20%, less than 10%, less than 5%, and less than 1%, respectively, by weight, by HPLC area, or both, or none of formulas I-4-E1, I-4-E2, and I-4-E3 are detectable. In some embodiments, the salt of formula I-4 can exist in the form of a mixture of any two or more of the four possible stereoisomers, formulas I-4-E1, I-4-E2, I-4-E3, and I-4-E4, in any ratio.

[0029] In some embodiments, L in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4) 1 The ampersand may be empty, in which case the C(O)-O group in formula I is directly bonded to the nitrogen-containing ring of formula I.

[0030] In some embodiments, L in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4) 1 C such as CH2 1-4 Alkylene is also acceptable.

[0031] In some preferred embodiments, L in formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-3, I-3-E1, I-3-E2, I-3-E3, or I-3-E4 1 is CH2. For example, in some embodiments, salts of formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-3, I-3-E1, I-3-E2, I-3-E3, or I-3-E4 may be characterized by having formula I-5. JPEG2023550798000016.jpg45170

[0032] In some preferred embodiments, L in formulas I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-4, I-4-E1, I-4-E2, I-4-E3, or I-4-E4 1 is empty, R 1 is hydrogen. For example, in some embodiments, salts of formulas I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-4, I-4-E1, I-4-E2, I-4-E3, or I-4-E4 may be characterized by having formula I-6. JPEG2023550798000017.jpg45170

[0033] Typically, R in equation I (e.g., equations I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5) 1 It is hydrogen.

[0034] In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5) 1 Also, C can be optionally substituted, such as cyclopentyl. 3-8 Carbocyclyl may also be used.

[0035] R in Equation I 2 Various groups are suitable for this purpose. Typically, R in formula I is suitable. 2R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 R in formula I may also be hydrogen. 2 If R is hydrogen, 1 It is typically not hydrogen.

[0036] In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 C is arbitrarily substituted. 1-6 It may be alkyl. For example, in some embodiments, R 2 F, OH, R A , OR A , and C optionally substituted with one or more substituents (e.g., 1, 2, or 3) independently selected from phenyl. 1-6 It may also be alkyl. Here, phenyl is a halogen (e.g., F or Cl), OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 It is optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the alkoxy. R in each occurrence A These are independently F, OH, and C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C is optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the alkoxy. 1-4 Alkyl or C3-6 It is cycloalkyl. In some embodiments, R 2 C 3-6 Alkyl, for example, isopropyl, branched C 3-6 Alkyl is also acceptable.

[0037] In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 C is arbitrarily substituted. 3-8 Carbocyclyl may also be used.

[0038] In some preferred embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 C is optionally substituted with cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 3-6 It may also be a cycloalkyl. For example, in some embodiments, R 2 F, OH, R A , and OR A C is optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the above. 3-6 It may also be a cycloalkyl. R in each appearance A These are independently F, OH, and C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C is optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the alkoxy. 1-4 Alkyl or C 3-6It is a cycloalkyl compound. In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 This may be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and more preferably cyclopentyl.

[0039] In some preferred embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 For example, a C that has one carbon-carbon double bond in the ring and can be optionally substituted. 4-7 It may be a cycloalkenyl. For example, in some embodiments, R 2 F, OH, R A , and OR A C can be optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of it. 4-7 It may also be a cycloalkenyl. Here, R in each occurrence A These are independently F, OH, and C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C is optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the alkoxy. 1-4 Alkyl or C 3-6is cycloalkyl. In some embodiments, R in Formula I (e.g., Formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 may be cyclopentenyl, JPEG2023550798000018.jpg28170

[0040] In some embodiments, R in Formula I (e.g., Formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 may be optionally substituted phenyl. For example, in some embodiments, R 2 is F, Cl, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy, and may be phenyl optionally substituted with one or more (e.g., 1, 2, or 3) substituents independently selected from them. In some embodiments, R in Formula I (e.g., Formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 may be phenyl.

[0041] In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2 R in formula I may be an optionally substituted 5 or 6-membered ring heteroalyl having 1 to 4 ring heteroatoms independently selected from N, O, and S, for example, as described herein. In some embodiments, R in formula I 2 The heteroalyl may be an optionally substituted five-membered ring having one to three ring heteroatoms independently selected from N, O, and S, such as oxazolyl or thiazolyl. In some embodiments, the five-membered ring heteroalyl is F, Cl, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) can be optionally substituted with one or more substituents (e.g., 1, 2, or 3) selected independently of the alkoxy. 2 teeth, It may also be an oxazolyl such as JPEG2023550798000019.jpg17170.

[0042] In some embodiments, R in formula I (e.g., formulas I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 2This could be, for example, an optionally substituted six-membered ring heteroalyl having one or two ring heteroatoms independently selected from N, O, and S, such as pyridyl or pyrimidinyl as disclosed herein. In some embodiments, the six-membered ring heteroalyl is F, Cl, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 The alkoxy can be optionally substituted with one or more substituents (e.g., one, two, or three) selected independently of it.

[0043] Typically, R in equation I (e.g., equations I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 3 C 1-6 Alkyl, more preferably methyl.

[0044] Typically, R in equation I (e.g., equations I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6) 4 C 1-6 It is alkyl, and more preferably methyl.

[0045] The anticholinergic activity of the salt of formula I is X - Since it does not depend on the properties of the counterion X in equation I -X is not particularly limited. Typically, it is X in equation I (e.g., equations I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, I-6). - This is a pharmaceutically acceptable counterion, for example, a halide (e.g., F - Cl - , Br - , or I - ) is. Other suitable counterions include those derived from various inorganic or organic acids such as sulfuric acid, nitric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. In some embodiments, X - It should be understood that this can also originate from a multivalent anion that cancels out the cation structure shown in equation I, such that the total charge of X is -1.

[0046] In some embodiments, the disclosure also provides salts selected from those shown in Table 1 below: JPEG2023550798000020.jpg109170X - It is a pharmaceutically acceptable counterion.

[0047] In some embodiments, the disclosure also provides salts selected from those shown in Table 2 below: JPEG2023550798000021.jpg182170X - It is a pharmaceutically acceptable counterion.

[0048] In some embodiments, to the extent applicable, the genera of compounds described herein also exclude any compounds or salts that were particularly known prior to this disclosure. In some embodiments, to the extent applicable, any sub-genera of species of compounds or salts prior to this disclosure that are entirely contained within the genera of compounds described herein may also be excluded from the genera herein. For example, to the extent applicable, glycopyrrolates or their precursors are excluded from the genera of compounds / salts described herein in relation to formula I or II.

[0049] Formula II The salts of formula I as used herein are typically derived from the corresponding amine having formula II, R 4 -Lg 1 R such as 4 It can be obtained by reacting with a group donor: JPEG2023550798000022.jpg37170Lg 1 is a leaving group such as a halide (e.g., I), Variable L 1 , R 1 , R 2 , R 3 , R 4 , and j may have any combination of any of the respective definitions set forth herein in relation to Formula I (including its sub-formulas).

[0050] In some embodiments, the present disclosure also provides compounds of formula II, or salts thereof. JPEG2023550798000023.jpg40170In formula, R 1 is hydrogen, or optionally substituted C 3-8 It is carbocyclyl. L 1 is empty, C 1-4 Alkylene, or C 1-4 It is a heteroalkylene, R 2 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8Carbocyclyl, a 4-8 membered heterocyclyl, phenyl, or a 5-10 membered heteroallyl, each of which can be optionally substituted. R 3 is hydrogen or C 1-6 It is alkyl, j is 0, 1, or 2.

[0051] In some embodiments, the compound of formula II may have the formula according to formula II-1. JPEG2023550798000024.jpg47170

[0052] In some embodiments, the compound of formula II may have the formula according to formula II-2. JPEG2023550798000025.jpg41170

[0053] L in Equation II (for example, Equation II-1 or II-2) 1 , R 1 , R 2 , R 3 The definitions of , and j include any of the respective definitions described herein in relation to Formula I (including its subformulas). For example, in some embodiments, L in Formula II 1 It may be empty. In some embodiments, L in formula II 1 C such as CH2 1-4 It may be an alkylene. In some embodiments, R in formula II 1 R may be hydrogen. In some embodiments, R in formula II 1 R in formula II may be cyclopentyl. In some embodiments, R in formula II 2 R may be hydrogen. In some embodiments, R in formula II 2 C, for example, can be optionally substituted as described herein, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 3-6 It may be a cycloalkyl. In some embodiments, R in formula II 2C, for example, can be optionally substituted as described herein, such as cyclopentenyl. 4-7 It may be a cycloalkenyl. In some embodiments, j in formula II is 1. In some embodiments, R in formula II 3 L in formula II is methyl. 1 , R 1 , R 2 , R 3 Other suitable bases or definitions of j include any combination of those discussed herein in relation to Formula I (including its subformulas).

[0054] In some embodiments, the compounds of formula II-2 can also be used to prepare pharmaceutically acceptable salts, such as acid addition salts or quaternary salts, like those having formula I.

[0055] The compounds of Formula II can be readily prepared by those skilled in the art in consideration of this disclosure and can be used for the preparation of the salts of Formula I discussed herein. Exemplary procedures are also shown in the Examples section.

[0056] For example, the compound of formula II can be prepared according to the following scheme A. Thus, compound A can be coupled with compound B under esterification conditions to obtain compound C, and then compound C is deprotected and optionally G is added to R. 2 By converting to R, it can be converted to the compound of formula II. As will be obvious to those skilled in the art, 2 The group can also be introduced early in the synthesis. Therefore, in some embodiments, R 2 The G group may be the same as the R group. 2 In embodiments that are not the same, it is typically under palladium-catalyzed cross-coupling conditions, such as R 2 The leaving group is a halide or sulfonate containing a leaving group that can react with the donor (e.g., O-Ts, O-Ms, O-Tf). Pg in compounds A and C 1 This is typically an oxygen protecting group, for example, as described herein. Pg 1Suitable protecting groups are not particularly limited. L in the compound shown in skim A 1 , R 1 , R 2 , R 3 The definitions of , and j include any combination of any of the respective definitions set forth herein in relation to Formula II (including its sub-formulas). JPEG2023550798000026.jpg98170

[0057] As will be apparent to those skilled in the art, conventional protecting groups are sometimes necessary to prevent certain functional groups from undergoing undesirable reactions. Protecting groups suitable for various functional groups, as well as suitable conditions for protecting and deprotecting specific functional groups, are well known in the art. For example, numerous protecting groups are described in "Protective Groups in Organic Synthesis," 4 th This is described in ed. PGMWuts; TW Greene, John Wiley, 2007, and the references cited herein. The reagents for the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA) and Sigma (St. Louis, Missouri, USA). Others are found in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplemental (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), and March's Advanced Organic Chemistry, (Wiley, 7 thThe preparation may be carried out by any of the procedures or obvious modifications thereof described in standard reference texts such as (Edition) and Larock's Comprehensive Organic Transformations (Wiley-VCH, 1999), or by any updates available at the time of this application.

[0058] Pharmaceutical composition Certain embodiments relate to pharmaceutical compositions comprising one or more compounds / salts of the present disclosure.

[0059] The pharmaceutical composition may optionally contain pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical composition comprises a compound / salt of the present disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable excipient. pharmaceutically acceptable excipients are well known in the art. Suitable non-limiting excipients include, for example, encapsulating materials or additives such as antioxidants, binders, buffers, carriers, coatings, colorants, diluents, disintegrants, emulsifiers, bulking agents, fillers, flavoring agents, wetting agents, lubricants, fragrances, preservatives, propellants, release agents, sterilizers, sweeteners, solubilizers, wetting agents, and mixtures thereof. See also Remington's The Science and Practice of Pharmacy, 21st Edition, ARGennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2005; incorporated herein by reference), which discloses various excipients used in compounding pharmaceutical compositions and known techniques for their preparation.

[0060] A pharmaceutical composition may contain any one or more of the compounds of this disclosure. For example, in some embodiments, a pharmaceutical composition may contain a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount for, for example, treating hyperhidrosis. In any of the embodiments described herein, the pharmaceutical composition may include a compound / salt selected from any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof.

[0061] The pharmaceutical compositions herein can be formulated for delivery via any known delivery route, including but not limited to oral, nasal, percutaneous, pulmonary, inhalation, oral cavity, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, subarachnoid, or parenteral administration. For example, in some embodiments, the pharmaceutical compositions herein can be formulated for topical delivery. In some embodiments, the pharmaceutical compositions herein can be formulated for oral administration. In some embodiments, the pharmaceutical compositions herein can be formulated for parenteral administration. In some embodiments, the pharmaceutical compositions herein can be formulated for inhalation, such as in aerosol sprays or dry powders. In some embodiments, the pharmaceutical compositions herein can be formulated as eye drops.

[0062] In some embodiments, pharmaceutical compositions can be prepared for oral administration. Oral formulations may be expressed as individual units such as capsules, pills, wafers, or troches, each containing a predetermined amount of the active compound, as powders or granules, as solutions or suspensions in aqueous or non-aqueous liquids, or as oil-in-water or water-in-oil emulsions. Excipients for preparing compositions for oral administration are known in the art. Non-limiting suitable excipients include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomer, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, crospovidone, diglycerides, ethanol, ethyl cellulose, ethyl laurate, ethyl oleate, fatty acid esters, gelatin, sprout oil, glucose, glycerin, and peanut oil. This product contains raw oil, hydroxypropyl methylcellulose, isopropanol, isotonic saline solution, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethylcellulose, sodium phosphate, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acid, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof.

[0063] In some embodiments, the pharmaceutical composition is formulated for parenteral administration (such as intravenous injection or drip infusion, subcutaneous injection or intramuscular injection). Parenteral formulations may be, for example, aqueous solutions, suspensions, or emulsions. Excipients for preparing parenteral formulations are known in the art. Non-limiting suitable excipients include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, sprout oil, peanut oil, liposomal, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, USP or isotonic saline, water, and mixtures thereof.

[0064] In some embodiments, pharmaceutical compositions can be prepared for topical administration. Topical formulations comprising one or more salts of the present disclosure can be prepared by mixing one or more salts with various carrier materials or pharmaceutically acceptable excipients. Suitable excipients for the preparation of topical formulations are known in the art. Some examples of suitable excipients include alcohol, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, PPG2, myristyl lactose propionate, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. Topical formulations may further optionally include lubricants such as talc, magnesium stearate, and mineral oil; humectants; emulsifiers and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; sweeteners; colorants; fragrances; and flavorings. When excipients function as diluents, excipients may be solids, semi-solids, or liquids that function as vehicles, carriers, or media for salts. In some embodiments, topical formulations according to this specification may be in the form of powders, suspensions, emulsions, solutions, syrups, alcohol solutions, ointments, topical cleansers, cleansing creams, skin gels, skin lotions, mousses, roll-ons, aerosols, or non-aerosol sprays of cream or gel formulations, and soft gelatin capsules. In some embodiments, pharmaceutical compositions may be formulated in the form of topical solutions, creams, ointments, mousses, gels, lotions, or powders. In some embodiments, the pharmaceutical composition may contain water, propylene glycol, citric acid, sodium citrate, tromethamine, alcohol (e.g., ethanol), and excipients such as preservatives.For example, exemplary topical formulations comprising one or more salts of the present disclosure may be in the form of topical solutions having an aqueous vehicle, an alcoholic vehicle, an aqueous alcoholic vehicle, etc., comprising one or more of water, propylene glycol, citric acid, sodium citrate, tromethamine, alcohol (e.g., ethanol), preservatives, polymers, and other excipients. In some embodiments, the topical solution may be formulated as a wipe that can be stored in a leak-proof pouch lined with linear low-density polyethylene (LLDPE), for example. Exemplary topical formulations comprising one or more salts of the present disclosure can be prepared in the same manner as described in U.S. Patent Nos. 6,433,003, 8,618,160, 9,744,105, 10,052,267, 8,859,610, 9,259,414, 10,004,717, 10,543,192, and 10,548,875.

[0065] The compounds / salts of this disclosure may be used alone, in combination with each other, or in combination with one or more additional therapeutic agents. When used in combination with one or more additional therapeutic agents, the compounds of this disclosure or the pharmaceutical compositions herein may be administered to the target simultaneously with such additional therapeutic agents or sequentially in any order. In some embodiments, a pharmaceutical composition may contain one or more compounds of this disclosure and one or more additional therapeutic agents in a single composition. In some embodiments, a pharmaceutical composition containing one or more compounds of this disclosure may be included in a kit which also includes separate pharmaceutical compositions containing one or more additional therapeutic agents.

[0066] A pharmaceutical composition may contain varying amounts of the compound of this disclosure, depending on various factors such as the intended use of the compound and its efficacy and selectivity. In some embodiments, the pharmaceutical composition contains a therapeutically effective amount of the compound / salt of this disclosure for the treatment of hyperhidrosis. In some embodiments, the pharmaceutical composition contains a therapeutically effective amount of the compound / salt of this disclosure (e.g., for hyperhidrosis) and a pharmaceutically acceptable excipient. When used herein, the therapeutically effective amount of the compound / salt of this disclosure is an amount effective for treating a disorder, condition or disease described herein, such as hyperhidrosis, and may depend on the person being treated, the disorder, condition or disease being treated and its severity, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the efficacy of the compound, its clearance rate, and whether or not another drug is being administered concurrently.

[0067] Treatment / Usage Methods The compounds / salts of the Disclosure have a variety of uses. For example, the compounds of the Disclosure can be used as therapeutic active substances for the treatment and / or prevention of disorders, conditions, or diseases associated with mAChR receptors, such as M3 receptors. Accordingly, some embodiments of the Disclosure also relate to methods of using one or more compounds of the Disclosure or pharmaceutical compositions of the Specified to treat or prevent disorders, conditions, or diseases that can respond to antagonism of mAChRs, such as M3 receptors, in subjects requiring such treatment, for example, to treat hyperhidrosis in subjects requiring such treatment.

[0068] In some embodiments, the Disclosure provides a method for treating or preventing a disorder, condition, or disease that can respond to M3 antagonism in a subject requiring such treatment. In some embodiments, the method involves administering an effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this Spec, or any pharmaceutically acceptable salt thereof) to a subject. Disorders, conditions, or diseases that may respond to M3 antagonism may include any of those described herein and any of those known in the art, such as hyperhidrosis, chronic obstructive pulmonary disease (COPD), pupillary dilation, and abdominal pain.

[0069] In some embodiments, the Disclosure provides a method for inhibiting the activity of mAChRs such as M3 receptors in a subject or biological sample. In some embodiments, the method involves contacting mAchRs such as M3 receptors with an effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or a pharmaceutically acceptable salt thereof), or an effective amount of a pharmaceutical composition described herein.

[0070] Hyperhidrosis is a disorder characterized by excessive sweating, that is, sweating in amounts exceeding what is necessary to regulate body temperature. It affects up to 1% of the population, and the primary group affected is women. The excessive sweating associated with hyperhidrosis can occur in the hands (palmar hyperhidrosis), armpits (axillary hyperhidrosis), or feet (plantar hyperhidrosis). Hyperhidrosis affects 8.8 million people in the United States alone, with an estimated 50.8% having axillary hyperhidrosis and 25-34% having palmar or plantar hyperhidrosis. The underlying cause of primary hyperhidrosis, or idiopathic hyperhidrosis, is not fully understood, but it is widely believed that excessive activity of the sympathetic nervous system is involved, as sweating is generally known to be under the control of the sympathetic nervous system. Secondary hyperhidrosis can be distinguished from primary hyperhidrosis by being caused by thyroid or pituitary disorders, diabetes mellitus, tumors, gout, menopause, or certain medications.

[0071] Various anticholinergic agents, such as eukatropin derivatives, oxybutynin, propantheline, benztropin, and various glycopyrrolate preparations, have been described as useful in the treatment of hyperhidrosis. See, for example, US Patent Nos. 4,720,494, 6,433,003, 8,618,160, 9,744,105, 10,052,267, 8,859,610, 9,259,414, 10,004,717, 10,543,192, and 10,548,875, as well as the prescription information for Qbrexza revised in June 2018. For example, referring to the Examples section, the compounds or salts of the present disclosure may have similar or better anticholinergic effects compared to these agents and may also be useful in the treatment of hyperhidrosis.

[0072] In some embodiments, the Disclosure provides a method for treating hyperhidrosis in a subject requiring it. In some embodiments, the method involves administering a therapeutically effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) or a therapeutically effective amount of a pharmaceutical composition described herein to a subject. For the treatment of hyperhidrosis, administration is typically carried out via a topical route. In some embodiments, hyperhidrosis is primary hyperhidrosis. In some embodiments, hyperhidrosis is secondary hyperhidrosis. In some embodiments, hyperhidrosis is primary axillary hyperhidrosis. In some embodiments, hyperhidrosis is primary palmar hyperhidrosis. In some embodiments, hyperhidrosis is primary plantar hyperhidrosis. Typically, the subjects are adult subjects or children aged 9 years or older.

[0073] The therapeutic methods described herein are not limited to hyperhidrosis. For example, in some embodiments, the disclosure also provides a method for treating peptic ulcers accompanied by excessive gastric acid production in a subject requiring it, the method comprising administering an effective amount of the compounds of the disclosure (e.g., compounds / salts of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) to a subject.

[0074] In some embodiments, the Disclosure also provides a method for reducing drooling in subjects requiring it, for example, children aged 3 to 16 years. In some embodiments, the method involves administering an effective amount of the compounds of the Disclosure (e.g., compounds / salts of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) to a subject.

[0075] In some embodiments, the Disclosure also provides a method for reducing gastric or respiratory secretions in subjects requiring such reduction. In some embodiments, the method involves administering an effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) to a subject.

[0076] In some embodiments, the Disclosure also provides a method for protecting the cardiac and nervous systems in subjects requiring such protection, for example, in patients under general anesthesia. In some embodiments, the method involves administering an effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this Spec, or any pharmaceutically acceptable salt thereof) to a subject.

[0077] In some embodiments, the Disclosure also provides a method for treating chronic obstructive pulmonary disease (COPD) in a subject requiring such treatment. In some embodiments, the method involves administering a therapeutically effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 herein, or any pharmaceutically acceptable salt thereof) to a subject. In some embodiments, the methods for treating COPD described herein may include administering to a subject one or more additional therapeutic agents effective in treating COPD. The additional therapeutic agents include, but are not limited to, bronchodilators, β-adrenergic receptor agonists, and anti-inflammatory agents, including but not limited to inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, JAK inhibitors, TYK2 inhibitors, NLRP3 inhibitors, PI3K inhibitors, SYK inhibitors, BTK inhibitors, IRAK1 and / or IRAK4 inhibitors, theophylline, and antibiotics, which are known in the art.

[0078] In some embodiments, the Disclosure also provides a method for inducing pupillary dilation in a subject requiring it. In some embodiments, the method involves administering an effective amount of a compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this Spec, or a pharmaceutically acceptable salt thereof) to a subject. Typically, a method for inducing pupillary dilation includes administering the compounds of this disclosure, formulated as eye drops.

[0079] In some embodiments, the Disclosure also provides a method for treating abdominal pain in subjects requiring it. In some embodiments, the method involves administering an effective amount of the compound of the Disclosure (e.g., a compound / salt of formula I (e.g., formula I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this Spec, or a pharmaceutically acceptable salt thereof) to a subject, or an effective amount of the pharmaceutical composition described herein. Typically, a method for treating abdominal pain involves oral administration of the compound of the Disclosure.

[0080] The administration in the methods described herein is not limited to any particular route of administration. For example, in some embodiments, administration may be performed orally, nasally, topically, percutaneously, into the lungs, by inhalation, in the cheek, sublingually, intraperitoneally, subcutaneously, by intramuscular injection, intravenously, rectally, intrapleurally, subarachnoidally, and parenterally. In some embodiments, administration may be performed topically. In some embodiments, administration may be performed orally. In some embodiments, administration may be performed parenterally.

[0081] As discussed herein, the compounds of this disclosure can be used as monotherapy or in combination therapy. In some embodiments of the methods described herein, the compounds of this disclosure can be administered as the sole active ingredient. In some embodiments, one or more compounds of this disclosure can be used in combination with additional therapies, for example, additional therapies effective in treating hyperhidrosis. In some embodiments of the methods described herein, one or more compounds of this disclosure can also be administered simultaneously or sequentially in any order to a subject in need, along with additional therapeutic agents, for example, agents effective in treating hyperhidrosis.

[0082] Dosage regimens including doses for the methods described herein may be modified and adjusted depending on the person being treated, the disorder, condition or disease being treated and its severity, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the efficacy of the compound, its clearance rate, and whether or not another drug is being administered concurrently.

[0083] definition This means that it is understood that the appropriate valence is maintained for all parts and their combinations.

[0084] It is also understood that certain embodiments of the variable portion in this specification may be the same as or different from other specific embodiments having the same identifier.

[0085] Appropriate groups in compounds of formulas I and II, or their subformulas, are selected independently, where applicable. The embodiments described herein can be combined. Such combinations are intended and within the scope of this disclosure. For example, R of formula I 1 , R 2 , R 3 , R 4 , L 1 , X - Any one or more of the definitions of , and j, if applicable, R 1 , R 2 , R 3 , R 4 , L 1 , X - , and j can be combined with any one or more other definitions, and the compounds obtained from the combinations are intended to be within the scope of this disclosure. Combinations of other variables in other formulas should be understood in the same way.

[0086] JPEG2023550798000027.jpg7170 does not show that the displayed portion is bonded to the rest of the molecule. As will be understood by those skilled in the art. Please note the following regarding JPEG2023550798000028.jpg6170.

[0087] Definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are based on the periodic table of elements, CAS version, and Handbook of Chemistry and Physics, 75. th Identified according to the ed. and inside cover, specific functional groups are generally defined as described therein. Furthermore, general principles of organic chemistry, as well as specific functional groups and reactivity, are described in Thomas Sorrell, *Organic Chemistry*, University Science Books, Sausalito, 1999; and Smith and March, *March's Advanced Organic Chemistry*, 5. thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd This is described in Edition, Cambridge University Press, Cambridge, 1987. This disclosure is not intended to be limited in any way by the exemplary list of substituents described herein.

[0088] The compounds described herein may contain one or more chiral centers and therefore may exist in various isomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers or geometric isomers, or in the form of a mixture of stereoisomers, including a racemic mixture and a mixture rich in one or more stereoisomers. The isomers can be isolated from the mixture by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts. Alternatively, preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p.268 (ELEliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). This disclosure further encompasses the compounds described herein as individual isomers substantially free from other isomers, or as mixtures of various isomers, including racemic mixtures. Where stereochemistry is specifically described, and unless inconsistent with the context, the compound may primarily exist as the stereoisomer described, with respect to its particular chiral center or axial chirality, in amounts less than 20%, less than 10%, less than 5%, less than 1%, or undetectable amounts of other stereoisomers, in weight, HPLC area, or both. The presence and / or amount of stereoisomers can be determined by those skilled in the art, taking into account this disclosure, including by the use of chiral HPLC.

[0089] If a range of values ​​is specified, it is intended to include each value and sub-range within that range. For example, "C1-6 ” is C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 It is intended to include

[0090] As used herein, the term “compound of the disclosure,” or where applicable, “salt of the disclosure,” means a compound described herein according to formula I (e.g., I-1, I-1-E1, I-1-E2, I-1-E3, I-1-E4, I-2, I-2-E1, I-2-E2, I-2-E3, I-2-E4, I-3, I-3-E1, I-3-E2, I-3-E3, I-3-E4, I-4, I-4-E1, I-4-E2, I-4-E3, I-4-E4, I-5, or I-6), formula II (e.g., formula II-1 or II-2). This refers to any of the salts, any of Examples 1 to 12, or any of the salts shown in Table 1 or 2 of this specification, their isotopically labeled compounds (such as deuterated analogs in which one or more hydrogen atoms are substituted with deuterium atoms in abundance exceeding their natural abundance), possible positional isomers, their possible stereoisomers (including diastereoisomers, enantiomers, and racemic mixtures), their tautomers, their conformational isomers, and / or their possible pharmaceutically acceptable salts (e.g., acid addition salts such as HCl salts or base addition salts such as Na salts). Hydrates and solvates of the compounds of this disclosure are considered compositions of this disclosure, where the compounds are bonded to water or a solvent, respectively.

[0091] The compounds of this disclosure may exist in isotopically labeled or isotopically enriched forms containing one or more atoms having atomic masses or mass numbers different from those most abundant in nature. The isotopes may be radioactive or non-radioactive. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine are: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl, and 125 This includes, but is not limited to, I. Compounds containing other isotopes of these and / or other atoms are within the scope of the present invention.

[0092] As used herein, the terms “administering” a compound or salt, and “administering” a compound or salt or other variant, mean providing a compound or salt or a prodrug of a compound or salt to an individual in need of treatment.

[0093] As used herein, the term "alkyl" refers to a linear or branched aliphatic saturated hydrocarbon, either by itself or as part of another group. In some embodiments, alkyl is a group of 1 to 12 carbon atoms (i.e., C 1-12 It may contain alkyl groups or a specified number of carbon atoms. In one embodiment, the alkyl group is a linear C 1-10 It is an alkyl group. In another embodiment, the alkyl group is a branched chain C 3-10 It is an alkyl group. In another embodiment, the alkyl group is a linear C 1-6 It is an alkyl group. In another embodiment, the alkyl group is a branched chain C 3-6 It is an alkyl group. In another embodiment, the alkyl group is a linear C 1-4 It is an alkyl group. For example, C 1-4Alkyl groups include methyl, ethyl, propyl (n-propyl), isopropyl, butyl (n-butyl), sec-butyl, tert-butyl, and iso-butyl. As used herein, the term "alkylene" refers to a divalent radical derived from an alkyl group, either by itself or as part of another group. For example, non-restrictive linear alkylene groups include -CH2-CH2-CH2CH2-, -CH2-CH2-CH2-, -CH2-CH2-, and so on.

[0094] As used herein, the term "alkenyl" refers to a linear or branched aliphatic hydrocarbon containing one or more carbon-carbon double bonds, for example, one, two, or three. In one embodiment, the alkenyl group is C 2-6 It is an alkenyl group. In another embodiment, the alkenyl group is C 2-4 These are alkenyl groups. Non-exclusive exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

[0095] As used herein, the term "alkynyl" refers to a linear or branched aliphatic hydrocarbon containing one or more carbon-carbon triple bonds, for example, one to three carbon-carbon triple bonds, either by itself or as part of another group. In one embodiment, the alkynyl has one carbon-carbon triple bond. In one embodiment, the alkynyl group is C 2-6 In another embodiment, the alkynyl group is C 2-4 These are alkynyl groups. Non-exclusive exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.

[0096] As used herein, the term "alkoxy" means, when used by itself or as part of another group, the formula OR a1 It refers to the radical of R a1 It is alkyl.

[0097] As used herein, the term "cycloalkoxy" means, when used by itself or as part of another group, the formula OR a1 It refers to the radical of R a1 It is a cycloalkyl group.

[0098] As used herein, the term “haloalkyl” refers to an alkyl group substituted with one or more fluorine, chlorine, bromine, and / or iodine atoms, either by itself or as part of another group. In preferred embodiments, a haloalkyl group is an alkyl group substituted with one, two, or three fluorine atoms. In one embodiment, the haloalkyl group is C 1-10 It is a haloalkyl group. In one embodiment, the haloalkyl group is C 1-6 It is a haloalkyl group. In one embodiment, the haloalkyl group is C 1-4 It is a haloalkyl group.

[0099] As used herein, the term “heteroalkyl” means, by itself or in combination with other terms, a stable linear or branched alkyl group having 2 to 14 carbon atoms, such as 2 to 10 carbon atoms in the chain, where one or more of the carbon atoms are substituted with heteroatoms selected from S, O, P, and N, and the nitrogen, phosphine, and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatoms S, O, P, and N may be located at any position within the heteroalkyl group or at a position where the alkyl group is bonded to the rest of the molecule. When a heteroalkyl group is said to be substituted, the substituent may replace one or more hydrogen atoms bonded to the heteroalkyl carbon atoms and / or heteroatoms. In some embodiments, heteroalkyl refers to a heteroalkyl group as defined herein having 1 to 4 carbon atoms. 1-4 It is heteroalkyl. C 1-4Examples of heteroalkyls include, but are not limited to, C4 heteroalkyls such as -CH2-CH2-N(CH3)-CH3, C3 heteroalkyls such as -CH2-CH2-O-CH3, CH2-CH2-NH-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, CH2-CH2-S(O)2-CH3, C2 heteroalkyls such as -CH2-CH2-OH, -CH2-CH2-NH2, -CH2-NH(CH3), -O-CH2-CH3, and C1 heteroalkyls such as -CH2-OH, -CH2-NH2, and -O-CH3. Similarly, the term "heteroalkylene" refers to divalent radicals derived from heteroalkyls, either by themselves or as part of another substituent, but not limited to those exemplified by -CH2-CH2-O-CH2CH2- and -O-CH2-CH2-NH-CH2-. For heteroalkylene groups, the heteroatom may occupy one or both of the chain ends (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Furthermore, for alkylene and heteroalkylene linking groups, the orientation of the linking group is not implied by the direction in which the linking group formula is written. "Heteroalkyl" is listed, followed by -NR'R ’’ When specific heteroalkyl groups such as are listed, it will be understood that the terms heteroalkyl and -NR'R'' are not redundant or mutually exclusive. Rather, specific heteroalkyl groups are listed for clarity. Therefore, the term "heteroalkyl" is used in conjunction with -NR'R''. ’’ It should not be interpreted as excluding certain heteroalkyl groups such as or .

[0100] When used by itself or as part of another group, "carbocyclyl" or "carbocyclic formula" refers to a non-aromatic ring system containing at least three carbon atoms, for example, 3 to 10 ring carbon atoms ("C"). 3-10The term "carbocyclyl" refers to a radical of a non-aromatic cyclic hydrocarbon group having zero heteroatoms. A carbocyclyl group may be monocyclic ("monocyclic carbocyclyl") or may contain condensed, crosslinked, or spirocyclic systems such as bicyclic carbocyclyl ("bicyclic carbocyclyl"), and may be saturated or partially unsaturated. Non-limiting exemplary carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclopentenyl, and cyclohexenyl. As used herein, the term "carbocyclylene," when used by itself or as part of another group, refers to a divalent radical derived from a carbocyclyl group as defined herein.

[0101] In some embodiments, "carbocyclyl" is completely saturated and is also called cycloalkyl. In some embodiments, cycloalkyl can have 3 to 10 ring carbon atoms ("C"). 3-10 (Cycloalkyl). In preferred embodiments, the cycloalkyl is a monocyclic ring. As used herein, the term "cycloalkylene" refers to a cycloalkylene group, either by itself or as part of another group, for example, This refers to divalent radicals derived from images such as JPEG2023550798000029.jpg19170.

[0102] "Heterocyclyl" or "heterocyclic" refers to a three-membered or more radical, such as a three- to fourteen-membered non-aromatic ring system having at least one ring heteroatom, such as a ring carbon atom and one to four ring heteroatoms, when used by itself or as part of another group, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyl groups containing one or more nitrogen atoms, the bond site may be a carbon or nitrogen atom, as long as the valence allows. Heterocyclyl groups may be monocyclic ("monocyclic heterocyclyl") or bicyclic ("bicyclic heterocyclyl") systems, such as condensed, bridged, or spirocyclic systems, and may be saturated or partially unsaturated. In heterocyclyl bicyclic systems, one or both rings may contain one or more heteroatoms, and the bond site may be on either ring. As used herein, the term “heterocyclylene” refers to a divalent radical derived from a heterocyclyl group as defined herein, either by itself or as part of another group. Heterocyclyl or heterocyclylene may optionally be linked to the rest of the molecule via carbon or nitrogen atoms.

[0103] Exemplary three-membered heterocyclyl groups containing one heteroatom include, non-limitingly, azilidinyl, oxyranyl, and thiiranyl. Exemplary four-membered heterocyclyl groups containing one heteroatom include, non-limitingly, azetidinyl, oxetanyl, and thietanyl. Exemplary five-membered heterocyclyl groups containing one heteroatom include, non-limitingly, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary five-membered heterocyclyl groups containing two heteroatoms include, non-limitingly, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidine-2-one. Exemplary five-membered heterocyclyl groups containing three heteroatoms include, indefinitely, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary six-membered heterocyclyl groups containing one heteroatom include, indefinitely, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary six-membered heterocyclyl groups containing two heteroatoms include, indefinitely, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary six-membered heterocyclyl groups containing two heteroatoms include, indefinitely, triazinanyl. Exemplary seven-membered heterocyclyl groups containing one heteroatom include, indefinitely, azepanyl, oxepanyl, and thiepanyl. Exemplary eight-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Exemplary five-membered heterocyclyl groups fused with a C6-allyl ring (also referred to herein as a 5,6-bicyclic heterocycle) include, but are not limited to, indolyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and others.Exemplary six-membered heterocyclyl groups fused with an allyl ring (also referred to herein as a 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl and tetrahydroisoquinolinyl.

[0104] "Allyl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) that, when used by itself or as part of another group, has 6 to 14 ring carbon atoms and 0 heteroatoms provided in the aromatic ring system ("C"). 6-14 In some embodiments, the allyl group has six ring carbon atoms ("C6 allyl," e.g., phenyl). In some embodiments, the allyl group has ten ring carbon atoms ("C6 allyl"). 10 "Allyl" (for example, naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, the allyl group has 14 ring carbon atoms ("C"). 14 "Allyl," for example, anthracyl. As used herein, the term "allylene," when used by itself or as part of another group, refers to a divalent radical derived from an allyl group as defined herein.

[0105] "Aralkyl," when used by itself or as part of another group, refers to an alkyl group substituted with one or more allyl groups, preferably one allyl group. Examples of aralkyls include benzyl and phenethyl. When we say that an aralkyl is optionally substituted, either the alkyl or allyl portion of the aralkyl can be optionally substituted.

[0106] "Heterallyl" refers to a radical of a monocyclic, bicyclic, or tricyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in the cyclic arrangement) having a ring carbon atom and at least one, preferably 1 to 4 ring heteroatoms, provided in the aromatic ring system, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5 to 14-membered ring heteroallyl"). In heteroallyl groups containing one or more nitrogen atoms, the bond site may be on a carbon or nitrogen atom, as long as the valence allows. A heteroallyl bicyclic ring system may contain one or more heteroatoms on one or both rings. For bicyclic heteroallyl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, etc.), the bond site may be on either ring, i.e., the ring containing the heteroatom (e.g., 2-indolyl) or the ring not containing the heteroatom (e.g., 5-indolyl). As used herein, the term “heteroallylene” refers to a divalent radical derived from a heteroallyle group as defined herein, either by itself or as part of another group.

[0107] An exemplary five-membered heteroallyl group containing one heteroatom includes, indefinitely, pyrrolyl, furanyl, and thiophenyl. An exemplary five-membered heteroallyl group containing two heteroatoms includes, indefinitely, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. An exemplary five-membered heteroallyl group containing three heteroatoms includes, indefinitely, triazolyl, oxadiazolyl, and thiadiazolyl. An exemplary five-membered heteroallyl group containing four heteroatoms includes, indefinitely, tetrazolyl. An exemplary six-membered heteroallyl group containing one heteroatom includes, indefinitely, pyridinyl. An exemplary six-membered heteroallyl group containing two heteroatoms includes, indefinitely, pyridazinyl, pyrimidinyl, and pyrazinyl. An exemplary six-membered heteroallyl group containing three or four heteroatoms includes, indefinitely, triazinyl and tetradinyl, respectively. Exemplary seven-membered ring heteroalyl groups containing one heteroatom include, non-limitingly, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroalyl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and prinyl. Exemplary 6,6-bicyclic heteroalyl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, synnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0108] "Heteroaralkyl" refers to an alkyl group that is substituted with one or more heteroalyl groups, preferably one heteroalyl group, when used by itself or as part of another group. When we say that a heteroaralkyl is optionally substituted, either the alkyl or heteroalyl portion of the heteroaralkyl can be optionally substituted.

[0109] The “optionally substituted” groups, such as optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted allyl, and optionally substituted heteroallyl groups, refer to the unsubstituted or substituted respective groups. In general, the term “substituted,” whether preceded by the term “optionally,” means that at least one hydrogen atom present on the group (e.g., a carbon or nitrogen atom) is substituted with an acceptable substituent, such as a substituent that results in a compound that is stable upon substitution, such as a compound that is not spontaneously converted by rearrangement, cyclization, elimination, or other reactions. Unless otherwise specified, an “optionally substituted” group has substituents at one or more substituted positions on the group, and if more than one position in any structure is substituted, the substituents may be the same or different at each position. Typically, when substituted, the optionally substituted groups herein can be substituted with 1 to 5 substituents. Substituents may be carbon atom substituents, nitrogen atom substituents, oxygen atom substituents, or sulfur atom substituents, where applicable. Any two of the substituents can bond to form an optionally substituted ring structure, such as a carbocyclyl (e.g., cycloalkyl), heterosilyl, aryle, or heteroaryle ring. Substitutions can occur with any available carbon, oxygen, or nitrogen atom and can form a spiro ring. Typically, the substitutions herein, with the exception of O-SO2-O, O-SO2-N, and N-SO2-N, do not result in OO, ON, SS, SN (except for SO2-N bonds), heteroatom-halogen, or -C(O)-S bonds, or three or more consecutive heteroatoms. However, in stable aromatic systems, some of such bonds or linkages may be permissible.

[0110] In a broad sense, the permissible substituents herein include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents may be one or more, the same or different, for a given organic compound. For the purposes of this disclosure, heteroatoms such as nitrogen may have any permissible substituents of the organic compounds described herein that satisfy the valence of the hydrogen substituent and / or the heteroatom. The substituents may include any substituents described herein, such as halogens, hydroxyls, carbonyls (carboxyls, alkoxycarbonyls, formyls, or acyls, etc.), thiocarbonyls (thioesters, thioacetates, or thioformates, etc.), alkoxys, cycloalkoxys, phosphoryls, phosphates, phosphonates, phosphinates, aminos, amides, amidines, imines, cyanos, nitros, azides, sulfhydryls, alkylthios, sulfates, sulfonates, sulfamoyls, sulfonyls, heterocyclyls, aralkyls, aryls, or heteroaryls, each of which may be substituted as appropriate.

[0111] Exemplary substituents include alkyl, alkenyl, alkynyl, allyl, heteroallyl, -alkylene-allyl, -allylen-alkyl, -alkylene-heteroallyl, -alkenylene-heteroallyl, -alkylene-heteroallyl, -OH, hydroxyalkyl, haloalkyl, -O-alkyl, -O-haloalkyl, -alkylene-O-alkyl, -O-allyl, -O-alkylene-allyl, acyl, -C(O)-allyl, halo, -NO2, -CN, -SF5, -C(O)OH, -C(O)O-alkyl, -C(O)O-allyl, -C(O)O-alkylene-allyl, -S(O)-alkyl, -S(O)2-alkyl, -S(O)-allyl, -S(O)2 This includes, but is not limited to, -allyl, -S(O)-heteroallyl, -S(O)2-heteroallyl, -S-alkyl, -S-allyl, -S-heteroallyl, -S-alkylene-allyl, -S-alkylene-heteroallyl, -S(O)2-alkylene-allyl, -S(O)2-alkylene-heteroallyl, cycloalkyl, heterocycloalkyl, -OC(O)-alkyl, -OC(O)-allyl, -OC(O)-cycloalkyl, -C(=N-CN)-NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), -N(Y1)(Y2), -alkylene-N(Y1)(Y2), -C(O)N(Y1)(Y2), and -S(O)2N(Y1)(Y2). Here, Y1 and Y2 may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, allyl, cycloalkyl, and alkylene-allyl.

[0112] Some examples of suitable substituents are (C1-C8) alkyl groups, (C2-C8) alkenyl groups, (C2-C8) alkynyl groups, (C3-C 10)Cycloalkyl groups, halogens (F, Cl, Br or I), halogenated (C1-C8) alkyl groups (e.g., -CF3, but not limited to -O-(C1-C8) alkyl groups, -OH, -S-(C1-C8) alkyl groups, -SH, -NH(C1-C8) alkyl groups, -N((C1-C8)alkyl)2 groups, -NH2, -C(O)NH2, -C(O)NH(C1-C8) alkyl groups, -C(O)N((C1-C8)alkyl)2, -NHC(O)H, -NHC(O)(C1-C8) alkyl groups, -NHC(O)(C3-C8) cycloalkyl groups, -N((C 1-C8)alkyl)C(O)H, -N((C1-C8)alkyl)C(O)(C1-C8)alkyl group, -NHC(O)NH2, -NHC(O)NH(C1-C8)alkyl group, -N((C1-C8)alkyl)C(O)NH2 group, -NHC(O)N((C1-C8)alkyl)2 group, -N((C1-C8)alkyl)C(O)N((C1-C8)alkyl)2 group, -N((C1-C8)alkyl)C(O)NH((C1-C8)alkyl), -C(O)H, -C(O)(C1-C8)alkyl group, -CN, -NO2, -S(O)(C1-C8)alkyl -S(O)2(C1-C8)alkyl group, -S(O)2N((C1-C8)alkyl)2 group, -S(O)2NH(C1-C8)alkyl group, -S(O)2NH(C3-C8)cycloalkyl group, -S(O)2NH2 group, -NHS(O)2(C1-C8)alkyl group, -N((C1-C8)alkyl)S(O)2(C1-C8)alkyl group, -(C1-C8)alkyl-O-(C1-C8)alkyl group, -O-(C1-C8)alkyl-O-(C1-C8)alkyl group, -C(O)OH, -C(O)O(C1-C8)alkyl group, NHOH, NHO(C1 -C8) alkyl groups, -O-halogenated (C1-C8) alkyl groups (e.g., -OCF3, but not limited), -S(O)2-halogenated (C1-C8) alkyl groups (e.g., -S(O)2CF3, but not limited), -S-halogenated (C1-C8) alkyl groups (e.g., -SCF3, but not limited), -(C1-C6) heterocyclic groups (e.g., pyrrolidine, tetrahydrofuran, pyran, or morpholine, but not limited), -(C1-C6) heteroalyl groups (e.g., tetrazole, imidazole, furan, pyrazine, or pyrazol, but not limited),This includes, but is not limited to, phenyl, -NHC(O)O-(C1-C6)alkyl, -N((C1-C6)alkyl)C(O)O-(C1-C6)alkyl, -C(=NH)-(C1-C6)alkyl, -C(=NOH)-(C1-C6)alkyl, or -C(=NO-(C1-C6)alkyl)-(C1-C6)alkyl.

[0113] Exemplary carbon atom substituents include halogens, -CN, -NO2, -N3, hydroxyl, alkoxy, cycloalkoxy, aryloxy, amino, monoalkylamino, dialkylamino, amide, sulfonamide, thiol, acyl, carboxylic acid, ester, sulfone, sulfoxide, alkyl, haloalkyl, alkenyl, alkynyl, and C. 3-10 Carbocyclyl, C 6-10 This includes, but is not limited to, allyls, 3- to 10-membered heterocyclyls, and 5- to 10-membered heteroalyls. For example, exemplary carbon atom substituents are F, Cl, -CN, -SO2H, -SO3H, -OH, and -OC. 1-6 Alkyl, -NH2, -N(C 1-6 Alkyl)2,-NH(C 1-6 Alkyl), -SH, -SC 1-6 Alkyl, -C(=O)(C 1-6 Alkyl), -CO2H, -CO2(C 1-6 Alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 Alkyl), -C(=O)NH2, -C(=O)N(C 1-6 Alkyl)2,-OC(=O)NH(C 1-6 Alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 Alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 Alkyl), -NHC(=O)N(C 1-6 Alkyl)2,-NHC(=O)NH(C 1-6 Alkyl), -NHC(=O)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6Alkyl)2,-SO2NH(C 1-6 Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocyclyl, C 6-10 It can include allyl, 3- to 10-membered heterocyclyl rings, and 5- to 10-membered heteroalyl rings. Alternatively, two geminal substituents can be bonded together to form =O.

[0114] The nitrogen atom may be substituted or unsubstituted, as long as its valence allows, and includes primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, acyl groups, esters, sulfones, sulfoxides, and C 1-10 Alkyl, C 1-10 Haloalkyl, C 2-10 Alkenil, C 2-10 Alkinyl, C 3-10 Carbocyclyl, a heterocyclyl with a 3-14 membered ring, C 6-14This includes, but is not limited to, allyls and 5- to 14-membered heteroalyl rings. Alternatively, two substituents bonded to the nitrogen atom are bonded to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroalyl ring. Each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, allyl, and heteroalyl can be further substituted as defined herein. In certain embodiments, substituents present on the nitrogen atom are nitrogen protecting groups (also called amino protecting groups). Nitrogen protecting groups are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, TW Greene and PGMWuts, 3rd edition, John Wiley & Sons, 1999, which are incorporated herein by reference. Exemplary nitrogen protecting groups include, but are not limited to, those that form carbamates such as carbobenzyloxy (Cbz) group, p-methoxybenzylcarbonyl (Moz or MeOZ) group, tert-butyloxycarbonyl (BOC) group, Troc, and 9-fluorenylmethyloxycarbonyl (Fmoc) group; those that form amides such as acetyl and benzoyl; those that form benzylamines such as benzyl, p-methoxybenzyl, and 3,4-dimethoxybenzyl; those that form sulfonamides such as tosyl and nosyl; and others such as p-methoxyphenyl.

[0115] Exemplary oxygen atom substituents include acyl groups, esters, sulfonates, and C 1-10 Alkyl, C 1-10 Haloalkyl, C 2-10 Alkenil, C 2-10 Alkinyl, C 3-10 Carbocyclyl, a heterocyclyl with a 3-14 membered ring, C 6-14This includes, but is not limited to, allyls and heteroalyls of 5- to 14-membered rings. Here, each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, allyl, and heteroalyl can be further substituted as defined herein. In certain embodiments, the oxygen atom substituent present on the oxygen atom is an oxygen protecting group (also called a hydroxyl protecting group). Oxygen protecting groups are well known in the art and are described in detail in Protective Groups in Organic Synthesis, TW Greene and PGMWuts, 3rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference. Exemplary oxygen-protecting groups include, but are not limited to, those that form alkyl ethers or substituted alkyl ethers such as methyl, allyl, benzyl, substituted benzyl (4-methoxybenzyl, methoxylmethyl (MOM), benzyloxymethyl (BOM), 2-methoxyethoxymethyl (MEM)), etc.; those that form silyl ethers such as trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), t-butyldimethylsilyl (TBDMS); those that form acetals or ketals such as tetrahydropyranyl (THP); those that form esters such as formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate; and those that form carbonates or sulfonates such as methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0116] Unless otherwise explicitly stated, combinations of substituents and / or variables are permissible only if such combinations result in a chemically acceptable and stable compound. A “stable” compound is one that can be prepared and isolated and whose structure and properties remain essentially unchanged, or can be kept essentially unchanged, for a sufficient period of time to use the compound for the purposes described herein (e.g., therapeutic administration to a subject).

[0117] In some embodiments, the “optionally substituted” alkyl, alkylene, heteroalkyl, heteroalkylene, alkenyl, alkynyl, carbocyclylene, cycloalkyl, cycloalkylene, alkoxy, cycloalkoxy, heterocyclyl, or heterocyclylene as used herein are each independently unsubstituted or F, Cl, -OH, protected hydroxyl, oxo (where applicable), NH2, protected amino, NH(C) 1-4 Alkyl) or its protected derivatives, N(C 1-4 Alkyl((C 1-4 Alkyl), C 1-4 Alkyl, C 2-4 Alkenil, C 2-4 Alkinyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The heteroalyl rings of five or six members containing one, two, or three ring heteroatoms independently selected from cycloalkoxy, phenyl, O, S, and N, and the heterocyclyl rings of three to seven members containing one or two ring heteroatoms independently selected from O, S, and N, can be substituted with one, two, three, or four substituents independently selected from these. Here, each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxyphenyl, heteroalyl, and heterocyclyl is F, -OH, oxo (where applicable), C 1-4 Alkyl and fluorosubstituted C 1-4 Alkyl (e.g., CF3), C 1-4 Alkoxy and fluorosubstituted C 1-4 The alkoxy is optionally substituted with one, two, or three substituents independently selected. In some embodiments, the "optionally substituted" allyl, allylene, heteroalyl, or heteroalylene groups as used herein are each independently unsubstituted or F, Cl, -OH, -CN, NH2, protected amino, NH(C) 1-4 Alkyl) or its protected derivatives, N(C 1-4 Alkyl((C 1-4Alkyl), -S(=O)(C 1-4 Alkyl), -SO2(C 1-4 Alkyl), C 1-4 Alkyl, C 2-4 Alkenil, C 2-4 Alkinyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The heteroalyl rings of 5 or 6 members containing 1, 2, or 3 ring heteroatoms independently selected from cycloalkoxy, phenyl, O, S, and N, and heterocyclyl rings of 3 to 7 members containing 1 or 2 ring heteroatoms independently selected from O, S, and N, can be substituted with 1, 2, 3, or 4 substituents independently selected from these. Here, each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroalyl, and heterocyclyl is F, -OH, oxo (where applicable), C 1-4 Alkyl and fluorosubstituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorosubstituted C 1-4 It is optionally substituted with one, two, or three substituents independently selected from the alkoxy.

[0118] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iod, -I).

[0119] The term "leaving group" is given its usual meaning in the field of organic synthesis chemistry and refers to an atom or group that can be substituted by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502). Suitable examples of leaving groups include, but are not limited to, halogens (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxys, allyloxycarbonyloxys, alkanesulfonyloxys, arenesulfonyloxys, alkylcarbonyloxys (e.g., acetoxy), allylcarbonyloxys, allyloxys, methoxy, N,O-dimethylhydroxylamino, picyl, and haloformates.

[0120] The term "pharmaceutically acceptable salt" refers to a salt that, within reasonable medical judgment, is suitable for use in contact with human and lower animal tissues without excessive toxicity, irritation, or allergic reactions, and that provides a reasonable benefit-risk ratio. Pharmaceutically acceptable salts are well known in the field.

[0121] The terms "tautomer" or "tautomer" refer to two or more interconvertible compounds resulting from tautomerization. The exact ratio of tautomers varies depending on several factors, such as temperature, solvent, and pH. Tautomerization is known to those skilled in the art. Exemplary tautomerizations include keto to enol, amide to imide, lactam to lactim, enamine to imine, and enamine to (different enamine).

[0122] As used herein, the term “subject” (also referred to herein as “patient”) refers to an animal, preferably a mammal, most preferably a human, that has been the subject of treatment, observation, or experimentation.

[0123] As used herein, terms such as “to treat,” “treating,” and “treatment” refer to the removal, reduction, or improvement of a disease or condition and / or symptoms associated therewith. Treating a disease or condition does not require, but is not excluded, the complete elimination of the disease, condition, or symptoms associated therewith. As used herein, terms such as “to treat,” “treating,” and “treatment” may include “preventive treatment,” which refers to reducing the possibility of recurrence of a disease or condition, or the possibility of a relapse of a previously controlled disease or condition, in subjects who do not have such a possibility but are at risk of recurrence or relapse of a disease or condition, or who are susceptible to recurrence or relapse of a disease or condition. The term “to treat” and its synonyms are intended to refer to the administration of a therapeutically effective amount of the compound described herein to a subject in need of such treatment.

[0124] The terms “effective dose” or “therapeutic dose” refer to the amount of a compound or combination of compounds described herein that is sufficient to achieve the intended use, including but not limited to the prevention or treatment of a disease. The therapeutic dose may vary depending on the intended use (in vitro or in vivo), the subject and disease state being treated (e.g., the subject’s weight, age, and sex), the severity of the disease state, the method of administration, etc., and can be readily determined by those skilled in the art. The term also applies to the dose that induces a particular response in target cells and / or tissues. The specific dose will vary depending on the particular compound selected, the dosing plan to be followed, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system through which the compound is carried.

[0125] As used herein, the singular forms “a,” “an,” and “the” include plural references unless it is clearly evident from the context that this is not explicitly stated or intended.

[0126] The term "and / or" as used in phrases such as "A and / or B" in this specification is intended to include both A and B, A or B, A (alone), and B (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0127] Headings and subheadings are used for convenience and / or for formal compliance purposes only and are not intended to limit the scope of the subject technology, nor are they to be referenced in connection with the interpretation of the description of the subject technology. Features described under one heading or subheading of this disclosure may be combined with features described under other headings or subheadings in various embodiments. Furthermore, not all features under a single heading or subheading may be used together in an embodiment.

[0128] Examples The various starting materials, intermediates, and compounds of the embodiments herein can be isolated and purified using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography, as appropriate. Crystallization of these compounds can be carried out using conventional methods such as melting point analysis, mass spectrometry, nuclear magnetic resonance, and various other spectroscopic analyses. Exemplary embodiments of the steps for synthesizing the products described herein are described in more detail below.

[0129] <Example 1> Synthesis of (3R)-3-(2-hydroxy-2-(2-(oxazo-l-2-yl)phenyl)acetoxy)-1,1-dimethylpyrrolidine-1-ium trifluoroacetic acid JPEG2023550798000030.jpg33170JPEG2023550798000031.jpg35170JPEG2023550798 000032.jpg37170JPEG2023550798000033.jpg37170JPEG2023550798000034.jpg37170

[0130] Step 1: To a solution of 2-(2-bromophenyl)acetic acid (S-1) (10 g, 0.047 mol) in MeOH (100 mL), concentrated H2SO4 (15.2 mL, 0.28 mol) was added dropwise. After addition, the resulting mixture was heated under reflux for 16 hours. The solvent was evaporated, and the residue was poured into ice water (100 mL). The mixture was extracted with EA (50 mL x 2), dried, and concentrated to obtain the crude product 2-(2-bromophenyl)acetic acid methyl (S-2). MS(ESI) m / z 229.1.

[0131] Step 2: A mixture of 2-(2-bromophenyl)methyl acetate (S-2) (10 g, crude product, 0.0467 mol), NBS (9 g, 0.051 mol), and AIBN (3.83 g, 0.023 mol) in CCl4 (100 mL) was heated under N2 at 80°C for 16 hours. The solvent was removed, the residue was diluted with DCM (150 mL), washed with water and brine, dried over Na2SO4, and concentrated to obtain 2-bromo-2-(2-bromophenyl)methyl acetate (S-3).

[0132] Step 3: To a solution of 4-methoxyphenol (S-4) (4.45 g, 0.0359 mol) in dry THF (250 mL), NaH (2.154 g, 0.054 mol) was added in small amounts under N2 at 0°C. The resulting mixture was stirred at 0°C for 30 minutes, followed by the addition of 2-bromo-2-(2-bromophenyl)acetate methyl (S-3) (15 g, crude product, 0.047 mol) and TBAI (776 mg, 0.007 mol). The resulting reaction mixture was stirred at room temperature for a further 16 hours. The reaction was quenched with aqueous NH4Cl (100 mL) at 0°C, and then extracted with EA (50 mL x 2). The combined organic phase was concentrated, and the residue was purified by silica gel column chromatography (PE / EA = 95:5~90:10) to obtain methyl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-5). 1 HNMR(400MHz,CDCl3):7.72-7.64(m,2H),7.43-7.38(m,1H),7.29-7.24(m,1H) ,6.98-6.94(m,2H),6.88-6.84(m,2H),6.10(s,1H),3.81(s,3H),3.79(s,3H).

[0133] Step 4: To a solution of methyl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-5) (1.0 g, 3.13 mmol) in MeOH (10 mL), THF (10 mL), and water (10 mL), LiOH (160 mg, 3.8 mmol) was added, and the resulting reaction mixture was stirred at 40°C for 16 hours. MeOH and THF were removed under vacuum, and the residue was diluted with HCl (1 N, 20 mL). This was extracted with EA (30 mL x 3), dried, and concentrated to obtain 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetic acid (S-6).

[0134] Step 5: To a solution of 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetic acid (S-6) (2.0 g, 5.931 mmol) in dry DCM (20 mL), (COCl)2 (0.75 mL, 8.897 mmol) and DMF (1 drop) were added at 0°C. The mixture was stirred at room temperature for 1 hour. Next, the reaction mixture was concentrated under vacuum to obtain 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetyl chloride (S-7) (2.1 g, crude product). The crude product was used in the next step without further purification.

[0135] Step 6: To a solution of 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetyl chloride (S-7) (2.1 g, 5.91 mmol) in dry DCM (20 mL), (R)-1-methylpyrrolidine-3-ol (S-8) (717 mg, 7.09 mmol) and TEA (1.8 g, 17.73 mmol) were added at 0°C. The resulting reaction mixture was stirred at room temperature for 2 hours. The reaction was quenched with water (30 mL) and extracted with DCM (30 mL x 3). The combined organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated, and the crude product was purified by silica gel column chromatography eluting with MeOH:DCM (0-5%) to obtain (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-9). MS(ESI)m / z422.1[M+H] + .

[0136] Step 7: A mixture of (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-9) (509 mg, 1.2 mmol), 2-(tributylstannyl)oxazole (S-10) (862 mg, 2.4 mmol), and Pd(PPh3)4 (277 mg, 0.24 mmol) in dioxane (15 mL) was stirred at 100 °C for 16 hours under N2. The solvent was removed, and the residue was purified by prep-TLC (DCM / MeOH = 10:1) to obtain (R)-1-methylpyrrolidine-3-yl 2-(4-methoxyphenoxy)-2-(2-(oxazole-2-yl)phenyl)acetate (S-11). MS(ESI) m / z 409.4 [M+H] + .

[0137] Step 8: To a solution of (R)-1-methylpyrrolidine-3-yl 2-(4-methoxyphenoxy)-2-(2-(oxazo-l-2-yl)phenyl)acetate (S-11) (80 mg, 0.2 mmol) in MeCN (15 mL) and water (15 mL), cerium ammonia nitrate (CAN) (550 mg, 1.0 mmol) was added. The resulting reaction mixture was stirred at room temperature for 20 hours. The solvent was removed under vacuum, and the residue was diluted with H2O and extracted with EA (15 mL x 3). The combined organic phases were dried and concentrated. The residue was purified by prep-HPLC to obtain (R)-1-methylpyrrolidine-3-yl 2-hydroxy-2-(2-(oxazo-l-2-yl)phenyl)acetate (S-12).

[0138] Step 9: CH3I (43 mg, 0.3 mol) was added to a solution of (R)-1-methylpyrrolidine-3-yl 2-hydroxy-2-(2-(oxazol-2-yl)phenyl)acetate (S-12) (9 mg, 0.03 mmol) in 2-butanone (3 mL). The reaction mixture was loaded into a sealed tube and heated overnight at 75 °C. The reaction mixture was concentrated, and the residue was purified by prep-HPLC to obtain trifluoroacetate (3R)-3-(2-hydroxy-2-(2-(oxazol-2-yl)phenyl)acetoxy)-1,1-dimethylpyrrolidine-1-ium (Example 1). 1 H-NMR (400MHz,D2O):7.94-7.90(m,2H),7.57-7.51(m,2H),7.42-7.36(m,1H),7.29-7.214( m,1H),6.01-5.95(m,1H),5.42(br,1H),3.76-3.33(m,3H),3.05(s,3H),2.77-2.69(m 3H),2.66-2.51(m,2H),2.17-2.08(m,1H),1.89-1.79(m,1H).MS(ESI)m / z 317.1[M+H] + .

[0139] <Examples 2 and 3> Synthesis of (3R)-3-(2-(2-(cyclopent-1-en-1-yl)phenyl)-2-hydroxyacetoxy)-1,1-dimethylpyrrolidine-1-ium trifluoroacetic acid JPEG2023550798000035.jpg35170JPEG2023550798000036.jpg36170JPEG2023550798 000037.jpg37170JPEG2023550798000038.jpg34170JPEG2023550798000039.jpg31170

[0140] Step 1: To a solution of 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetyl chloride (S-7) (2.1 g, 5.91 mmol) in dry DCM (20 mL), (R)-1-methylpyrrolidine-3-ol (S-8) (717 mg, 7.09 mmol) and TEA (1.8 g, 17.73 mmol) were added in an ice bath. The mixture was stirred at room temperature for 2 hours. The mixture was quenched with water (30 mL) and extracted with DCM (30 mL x 3). The organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with MeOH:DCM (0-5%) to obtain (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-13). MS(ESI)m / z 422.1[M+H] + .

[0141] Step 2: Add CAN (6.14 g, 11.206 mmol) to a CH3CN / H2O (30 mL / 6 mL) solution of (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-13) (1.57 g, 3.74 mmol). Stir the mixture overnight at room temperature. Quench the mixture with water (30 mL) and extract with EA (30 mL x 3). Wash the organic layer with HCl (0.5 M, 20 mL x 2). Base the aqueous layer to pH = 9 with aqueous Na2CO3 solution. Extract the mixture with EA (30 mL x 3). Dry the combined organic layers over Na2SO4 and filter. The filtrate was concentrated to obtain (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-hydroxyacetate (S-14) (600 mg, crude product), which was used directly in the next step without further purification. MS(ESI)m / z 316.0[M+H] + .

[0142] Step 3: 1,4-Dioxane (15 mL) containing (R)-1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-hydroxyacetate (S-14) (480 mg, 1.529 mmol), cyclopent-1-en-1-ylboronic acid (S-15) (257 mg, 2.293 mmol), and K3PO 4( A mixture of 972 mg (4.587 mmol) and Pd(dppf)Cl2 (112 mg, 0.153 mmol) was heated at 110°C for 16 hours under a nitrogen atmosphere. The mixture was quenched with water (30 mL) and extracted with EA (30 mL x 3). The combined organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with MeOH:DCM (0-10%) to obtain a diastereomer mixture of (R)-1-methylpyrrolidine-3-yl 2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetate. This was further separated into the rapidly eluting isomer S-16a and the slowly eluting isomer S-16b using Daicel column IH elution with Hex-EtOH (9:1).

[0143] Step 4: To a solution of S-16a (70.0 mg, 0.233 mmol) in 2-butanone (3 mL), CH3I (3 drops) was added. The mixture was stirred at 75°C for 4 hours. The mixture was concentrated and purified by prep-HPLC to obtain trifluoroacetic acid (R)-3-(-2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetoxy)-1,1-dimethylpyrrolidine-1-ium (Example 2). 1 H NMR(400MHz,D2O):δ=7.47-7.39(m,4H),5.89(t,J=2.0Hz,1H),5.71(s,1H),5.57(t,J=6Hz,1H),3.89-3.77(m,2H),3.61-3.48(m MS (ESI)m / z 316.2[M+H] + .

[0144] Example 3 was prepared from S-16b using the same method as in Example 2. 1 H NMR(400MHz,D2O):δ=7.46-7.37(m,4H),5.89(t,J=2.0Hz,1H),5.72 (s,1H),5.61(br,1H),3.82-3.78(dd,1H),3.71-3.57(m,2H),3.53(d,1H),3.16(s,3H),2.81-2.75(m ,1H),2.76(s,3H),2.73-2.68(m,2H),2.59-2.55(m,2H),2.42-2.34(m,1H),2.05(quint,2H).MS(ESI) m / z 316.2[M+H] + .

[0145] <Examples 4 and 5> Synthesis of (3S)-3-(2-(2-(cyclopent-1-en-1-yl)phenyl)-2-hydroxyacetoxy)-1,1-dimethylpyrrolidine-1-ium trifluoroacetic acid JPEG2023550798000040.jpg31170

[0146] Examples 4 and 5 were synthesized starting from (S)-1-methylpyrrolidine-3-ol in the same manner as described for Examples 2 and 3. Here, Example 4 was derived from the fast-eluting isomer of (S)-1-methylpyrrolidine-3-yl 2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetate, and Example 5 was derived from the corresponding slow-eluting isomer. 1 The 1H NMR looked the same as in Example 3, and in Example 5. 1 The 1H NMR spectrum appears the same as in Example 2.

[0147] <Examples 6 and 7> Synthesis of trifluoroacetic acid (R)-2-((2-(2-(cyclopent-1-en-1-yl)phenyl)-2-hydroxyacetoxy)methyl)-1,1-dimethylpyrrolidine-1-ium JPEG2023550798000041.jpg32170JPEG2023550798000042.jpg31170JPEG2023550798 000043.jpg32170JPEG2023550798000044.jpg33170JPEG2023550798000045.jpg37170

[0148] Step 1: To a solution of (R)-(1-methylpyrrolidine-2-yl)methylethanol (0.68 g, 5.9 mmol) and TEA (1.19 g, 11.8 mmol) in DCM (20 mL), 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetyl chloride (S-7) (2.1 g, 5.9 mmol) in DCM (10 mL) was added over 20 minutes at 0°C. The resulting reaction mixture was stirred at 45°C for 2 hours. The mixture was quenched with H2O and extracted with DCM. The combined organic phase was dried over Na2SO4 and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (PE / EA=1 / 1) to obtain ((R)-1-methylpyrrolidine-2-yl)methyl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-17). MS(ESI)m / z433.9[M+H] + .

[0149] Step 2: CAN (8.0 g, 14.6 mmol) was added to a CH3CN / H2O (10 mL / 10 mL) solution of ((R)-1-methylpyrrolidine-2-yl)methyl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-17) (2.1 g, 4.9 mmol). The resulting reaction mixture was stirred overnight at room temperature. The mixture was concentrated, the residue was diluted with water (50 mL), and extracted with EA (50 mL). The aqueous solution was adjusted to pH=9 using Na2CO3 solution. The resulting mixture was extracted with EA (100 mL x 2). The combined organic phases were washed with brine, dried over Na2SO4, and concentrated to obtain the crude product ((R)-1-methylpyrrolidine-2-yl)methyl 2-(2-bromophenyl)-2-hydroxyacetate (S-18) (0.9 g, yield: 56.6%), which was used directly in the next step without further purification. MS(ESI)m / z327.9[M+H] + .

[0150] Step 3: A mixture of ((R)-1-methylpyrrolidine-2-yl)methyl 2-(2-bromophenyl)-2-hydroxyacetate (S-18) (0.8 g, 2.4 mmol), cyclopent-1-en-1-ylboronic acid (S-15) (0.4 g, 3.6 mmol), K3PO4 (1.01 g, 4.8 mmol), and Pd(dppf)Cl2 (0.18 g, 0.24 mmol) in dioxane / H2O (10 mL / 1 mL) was stirred overnight at 100°C under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (50 mL). The organic phase was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by prep-HPLC to obtain a diastereomer mixture of ((R)-1-methylpyrrolidine-2-yl)methyl 2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetate (S-19) (0.25 g, yield: 32.5%) as a brown oily substance. Further separation was performed by Daicel chiral column IH eluting with hexane:EtOH (9:1, containing 0.3% DEA) to obtain S-19a as the fast-eluting isomer and S-19b as the slow-eluting isomer.

[0151] Step 4: CH3I (1 mL) was added to a solution of S-19a (30 mg, 0.095 mmol) in 2-butanone (1 mL). The resulting reaction mixture was loaded into a sealed tube and stirred at 65°C for 2 hours. The mixture was concentrated and purified by prep-HPLC (with 0.1% TFA as an additive) to obtain one enantiomer of trifluoroacetic acid (R)-2-((2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetoxy)methyl)-1,1-dimethylpyrrolidine-1-ium of Example 6. 1 H NMR(400MHz,D2O):7.36-7.26(m,4H) 5.79-5.78(t,J=2.2Hz,1H),5.63(s,1H),4.68-4.64(m,1H),4.28-4.22(m,1H),3.74-3.67(m,1H),3.36-3.28(m,2H),2.7 0(s,3H),2.67(s,3H),2.64-2.58(m,2H),2.51-2.44(m,2H),2.26-2.20(m,1H),2.07-1.82(m,5H).MS(ESI)m / z330.2[M+H] + .

[0152] Example 7 was prepared from S-19b. 1 H NMR(400MHz,D2O):7.38-7.31(m,4H)5.80-5.79(t,J=2.0Hz,1H),5.65(s,1H),4.50-4.38(m,2H),3.85-3.81(m,1H),3.41-3.37(m,2H) ),2.69(s,3H),2.63-2.58(m,5H),2.51-2.46(m,2H),2.24-2.22(m,1H),2.04-1.83(m,4H),1.71-1.66(m,1H).MS(ESI)m / z330.2[M+H] + .

[0153] <Examples 8 and 9> Synthesis of trifluoroacetic acid (S)-2-((2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetoxy)methyl)-1,1-dimethylpyrrolidine-1-ium JPEG2023550798000046.jpg21170

[0154] Examples 8 and 9 were synthesized starting from (S)-(1-methylpyrrolidine-2-yl)methylethanol in the same manner as described for Examples 6 and 7. Here, Example 8 was derived from the fast-eluting isomer of ((S)-1-methylpyrrolidine-2-yl)methyl 2-(2-(cyclopento-1-en-1-yl)phenyl)-2-hydroxyacetate, and Example 9 was derived from the corresponding slow-eluting isomer. 1 The 1H NMR looked the same as in Example 6, and also the same as in Example 9. 1 The 1H NMR spectrum appears similar to that of Example 7.

[0155] <Example 10> Synthesis of 3-[2-(2-cyclopentylphenyl)-2-hydroxyacetoxy]-1,1-dimethylpyrrolidinium chloride JPEG2023550798000047.jpg36170JPEG2023550798000048.jpg32170JPEG2023550798000049.jpg33170

[0156] Step 1: To a solution of 1-methylpyrrolidine-3-ol (300 mg, 2.97 mmol) and TEA (400 mg, 3.95 mmol) in DCM (15 mL), 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetyl chloride (S-7) (710 mg, 1.98 mmol) was added over 10 minutes at 0°C. The mixture was stirred at room temperature for 2 hours. The mixture was quenched with H2O and extracted with DCM. The combined organic phase was dried over Na2SO4 and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (PE / EA = 1 / 1) to obtain 1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-20). MS(ESI) m / z 422.1[M+H] + .

[0157] Step 2: To a mixture of 1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-20) (710 mg, 1.69 mmol) in dioxane / H2O (25 mL / 5 mL), cyclopento-1-en-1-ylboronic acid (S-5) (491 mg, 2.53 mmol), K2CO3 (699 mg, 5.07 mmol), and Pd(dppf)Cl2 (123 mg, 0.169 mmol) were added. The resulting mixture was degassed and packed with N2. The reaction mixture was then stirred overnight at 110°C. The reaction mixture was diluted with water (20 mL) and extracted with EA (50 mL). The organic phase was washed with brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH=20 / 1) to obtain 1-methylpyrrolidine-3-yl(2-cyclopent-1-enylphenyl)-(4-methoxyphenoxy)acetate (S-21). MS (ESI) m / z 408.2[M+H] + .

[0158] Step 3: To a solution of 1-methylpyrrolidine-3-yl(2-cyclopent-1-enylphenyl)-(4-methoxyphenoxy)acetate (S-21) (330 mg, 0.81 mmol) in 2-butanone (5 mL), K2CO3 (20 mg, 0.081 mmol) and CH3I (571 mg, 4.05 mmol) were added. The resulting reaction mixture was loaded into a sealed tube and stirred overnight at 75°C. The mixture was concentrated and purified by prep-HPLC to obtain trifluoroacetate 3-[2-(2-cyclopent-1-enylphenyl)-2-(4-methoxyphenoxy)acetoxy]-1,1-dimethylpyrrolidinium (S-22). MS (ESI) m / z 422.3 [M] + .

[0159] Step 4: A mixture of 3-[2-(2-cyclopent-1-enyl-phenyl)-2-(4-methoxy-phenoxy)-acetoxy]-1,1-dimethyl-pyrrolidinium trifluoroacetate (S-22) (81 mg, 0.189 mmol) and Pd / C (~20 mg, 20 wt%) in MeOH (10 mL) was degassed and filled with hydrogen using a balloon. Next, the resulting mixture was hydrogenated at room temperature for 16 h. The reaction mixture was filtered through celite and concentrated to give the crude product 3-[2-(2-cyclopentyl-phenyl)-2-(4-methoxy-phenoxy)-acetoxy]-1,1-dimethyl-pyrrolidinium trifluoroacetate (S-23), which was used as such in the next step. MS (ESI) m / z 424.3 [M] + .

[0160] Step 5: CAN (625 mg, 1.14 mmol) was added in two portions at room temperature to a mixture of the crude product 3-[2-(2-cyclopentyl-phenyl)-2-(4-methoxy-phenoxy)-acetoxy]-1,1-dimethyl-pyrrolidinium trifluoroacetate (S-23) (80 mg, 0.189 mmol) in CH3CN / H2O (5 mL / 5 mL). The resulting reaction mixture was stirred at room temperature overnight. The mixture was concentrated, the residue was diluted with water (10 mL) and extracted with EA (10 mL x 2). The aqueous solution was adjusted to pH = 9 using a Na2CO3 solution and extracted again with EA (10 mL x 2). The combined organic phases were dried over Na2SO4 and concentrated. The residue was purified by prep-HPLC (0.1% TFA as additive), the product was treated with a few drops of HCl and lyophilized to give 3-[2-(2-cyclopentyl-phenyl)-2-hydroxy-acetoxy]-1,1-dimethyl-pyrrolidinium chloride (Example 10). 11H NMR (400 MHz, D2O, mixture of two diastereomers): 7.44 - 7.42 (m, 2H, both diastereomers), 7.36 - 7.33 (m, 2H, both diastereomers), 7.27 - 7.20 (m, 2H, both diastereomers), 5.72 (s, 1H, diastereomer - 1), 5.70 (s, 1H, diastereomer - 2), 5.54 (br, 2H, both diastereomers), 3.81 - 3.68 (m, 3H, both diastereomers), 3.63 - 3.41 (m, 5H, both diastereomers), 3.12 (s, 3H, diastereomer - 1), 3.08 (s, 3H, diastereomer - 2), 2.86 (s, 3H, diastereomer - 1), 2.73 - 2.64 (m, 5H, both diastereomers), 2.32 - 2.29 (m, 1H, diastereomer - 1), 2.08 - 1.92 (m, 5H, both diastereomers), 1.77 - 1.51 (m, 12H, both diastereomers). MS (ESI) m / z 318.2 [M] + .

[0161] <Example 11> Synthesis of 3-(2-([1,1'-biphenyl]-2-yl)-2-hydroxyacetoxy)-1,1-dimethylpyrrolidin-1-ium chloride JPEG2023550798000050.jpg39170JPEG2023550798000051.jpg35170JPEG2023550798000052.jpg37170

[0162] Step 1: A mixture of methyl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-5) (1.06 g, 3.02 mmol), phenylboronic acid (553 mg, 4.53 mmol), KOAc (444 mg, 4.53 mmol), and Pd(PPh3)4 (175 mg, 0.15 mmol) in CH3CN / H2O (75 mL / 16 mL) was degassed and packed with N2. The resulting mixture was then heated overnight at 80°C. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (PE / EA = 10 / 1) to obtain methyl 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetate (S-24). MS (ESI) m / z 366.2 [M+18] + .

[0163] Step 2: To a solution of methyl 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetate (S-24) (908 mg, 2.6 mmol) in MeOH / THF / H2O (10 mL / 10 mL / 10 mL), LiOH / H2O (131 mg, 3.12 mmol) was added. The resulting mixture was stirred overnight at 40°C. The reaction mixture was concentrated. The residue was diluted with water (10 mL), acidified with dilute HCl until the pH was 2, and extracted with EA (20 mL x 3). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, and concentrated to obtain 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetic acid. MS (ESI) m / z 333.2 [MH] - .

[0164] Step 3: To a mixture of 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetic acid (890 mg, 2.6 mmol) in DCM (15 mL), DMF (1 drop) and oxalyl dichloride (500 mg, 3.9 mmol) were added dropwise at 0°C. The mixture was stirred at room temperature for 2 hours. Next, the mixture was concentrated to obtain biphenyl-2-yl-(4-methoxyphenoxy)-acetyl chloride (S-25), which was used as is in the next step.

[0165] Step 4: To a mixture of 1-methylpyrrolidine-3-ol (240 mg, 2.36 mmol) and TEA (290 mg, 2.83 mmol) in DCM (20 mL), a mixture of 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetyl chloride (S-25) (900 mg, 2.60 mmol) in DCM (10 mL) was added dropwise over 20 minutes at 0°C. After the addition, the mixture was stirred for a further 2 hours and the temperature was slowly increased to room temperature. LC-MS indicated completion of the reaction. The mixture was quenched with water and extracted with DCM (30 mL x 3). The combined organic phase was dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (DCM / MeOH=20 / 1) to obtain 1-methylpyrrolidine-3-yl 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetate (S-26). MS (ESI) m / z 418.2[M+H] + .

[0166] Step 5: A pressure tube filled with 1-methylpyrrolidine-3-yl 2-([1,1'-biphenyl]-2-yl)-2-(4-methoxyphenoxy)acetate (S-26) (840 mg, 1.85 mmol) and MeI (1.15 mL, 18.5 mmol) in 2-butanone (10 mL) was sealed and heated at 75 °C for 16 hours. The cooled reaction mixture was concentrated, the residue was purified by prep-HPLC (with 0.1% TFA as an additive), the product fraction was treated with HCl, and lyophilized to obtain 3-(2-([1,1'-biphenyl]-2-yl)-2-hydroxyacetoxy)-1,1-dimethylpyrrolidine-1-ium chloride (S-27) as a yellow oily substance. MS (ESI) m / z 432.2[M] + .

[0167] Step 6: CAN (800 mg, 1.46 mmol) was added to a mixture of 3-[2-biphenyl-2-yl-2-(4-methoxyphenoxy)-acetoxy]-1,1-dimethylpyrrolidinium (S-27) (10 mL / 10 mL) trifluoroacetate in CH3CN / H2O (10 mL / 10 mL). The resulting mixture was stirred overnight at room temperature. The mixture was concentrated, and the residue was purified by prep-HPLC (with 0.1% TFA as an additive) to obtain 3-(2-biphenyl-2-yl-2-hydroxyacetoxy)-1,1-dimethylpyrrolidinium trifluoroacetate (Example 11). 1 H NMR(400MHz,D2O):7.50-7.39(m,6H),7.38-7.35(m,3H),5.41(s,1H),5.36(br,1H),3.73-3.66(m,1H),3.60-3.41(m,3H),3.23-3.12 (m,3H),2.83-2.72(m,3H),2.64-2.56(m,1H),2.20-1.98(m,1H). MS (ESI) m / z 326.2 [M] + .

[0168] <Example 12> Synthesis of 3-(2-hydroxy-2-(2-isopropylphenyl)acetoxy)-1,1-dimethylpyrrolidine-1-ium chloride JPEG2023550798000053.jpg29170JPEG2023550798000054.jpg44170JPEG2023550798000055.jpg34170

[0169] Step 1: A mixture of 1-methylpyrrolidine-3-yl 2-(2-bromophenyl)-2-(4-methoxyphenoxy)acetate (S-20) (500 mg, 1.19 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (240 mg, 1.43 mmol), K2CO3 (328 mg, 2.38 mmol), and Pd(PPh3)4 (137 mg, 0.12 mmol) in dioxane / H2O (10 mL / 1 mL) was stirred overnight at 100°C under N2. The reaction mixture was diluted with water (20 mL) and extracted with EA (20 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography eluting with EA to obtain 1-methylpyrrolidine-3-yl 2-(4-methoxyphenoxy)-2-(2-(prop-1-en-2-yl)phenyl)acetate (S-28). MS (ESI) m / z 382.2 [M+H] + .

[0170] Step 2: To a solution of 1-methylpyrrolidine-3-yl 2-(4-methoxyphenoxy)-2-(2-(propa-1-en-2-yl)phenyl)acetate (S-28) (300 mg, 0.78 mmol) in MeOH (5 mL), Pd / C (80 mg) was added. The mixture was stirred under H2 at room temperature for 4 hours. The reaction mixture was filtered, and the filtrate was concentrated to obtain 1-methylpyrrolidine-3-yl 2-(2-isopropylphenyl)-2-(4-methoxyphenoxy)acetate (S-29). MS (ESI) m / z 384.2 [M+H] + .

[0171] Step 3: To a mixture of 1-methylpyrrolidine-3-yl 2-(2-isopropylphenyl)-2-(4-methoxyphenoxy)acetate (S-29) (270 mg, 0.71 mmol) in CH3CN / H2O (5 mL / 5 mL), CAN (1.16 g, 2.11 mmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated. Next, the residue was diluted with water (10 mL) and extracted with EA (20 mL). The aqueous solution was adjusted to pH 9 using Na2CO3 solution. The resulting mixture was extracted with EA (20 mL x 2). The combined organic phase was washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated to obtain 1-methylpyrrolidine-3-yl 2-hydroxy-2-(2-isopropylphenyl)acetate (S-30) as a brown solid, which was used in the next step without further purification. MS (ESI) m / z 278.2[M+H] + .

[0172] Step 4: CH3I (1 mL) was added to a mixture of 1-methylpyrrolidine-3-yl 2-hydroxy-2-(2-isopropylphenyl)acetate (S-30) (100 mg, 0.29 mmol) in 2-butanone (2 mL). The mixture was stirred at 65°C for 2 hours. The reaction mixture was concentrated to obtain the crude product. The crude product was purified by prep-HPLC (with 0.1% TFA as an additive). The product was treated with HCl and lyophilized to obtain 3-(2-hydroxy-2-(2-isopropylphenyl)acetoxy)-1,1-dimethylpyrrolidine-1-ium chloride, Example 12. 1 H NMR(400MHz,D2O):7.44(d,J=8Hz,1H),7.40-7.35(m,1H),7.27-7.22(m,2H),5.71(d,J=9.2Hz,1H),5.54(br,1H),3.83-3.71(m, 2H),3.64-3.45(m,2H),3.31-3.21(m,1H),3.13,3.08(s,3H),2.90,2.73(s,3H),2.71-2.66(m,1H),2.34-2.30(m,1H),2.13-2.06 (m, 1H),1.24-1.13(m,6H).MS(ESI)m / z 292.2 [M] + .

[0173] <Biological Example 1> In vitro assay for determining IC50 The efficacy of the compound was evaluated using the FLIPR assay. CHO-K1 cells stably expressing the M3 receptor were cultured at 37°C in a cell culture incubator (ThermoFisher, 5% CO2) in medium (90% ham F-12 nutrient mixture, Gibco; 10% fetal bovine serum, Biosera; 200 μg / mL hygromycin, and penicillin (100 U / mL) / streptomycin (100 μg / mL), Invitrogen) until the culture density reached 100%. Cells were harvested using 0.25% trypsin / EDTA and centrifuged at 300 × g for 5 minutes, resulting in 5 × 10⁶ cells. 5The cells were resuspended in culture medium at a cell density of cells / mL. 20 microliters of cell suspension (10,000 cells / well) were transferred to a 384-well plate and cultured for 24 hours prior to the assay. DMSO was used as a blank control, and scopolamine (MedChemExpress) was used as a positive control for the antagonist. The compound was prepared in DMSO (stock concentration: 1 mM) and serially diluted 3× times on a 384-LDV plate (Labcyte) (10 concentrations). 90 nL of the serially diluted compound was transferred from the 384-LDV plate to a compound plate (PerkinElmer) using an Echo 550 (Labcyte), and 30 μL of assay buffer (1× HBSS with 20 mM HEPES, pH 7.4, Sigma) was added to each well. For the FLIPR assay, the culture medium was removed and 20 μL of 1x loading dye (assay buffer containing 2 μM Fluo-8 AM, AAT Bioquest; 1 mM probenecid and 0.0025% Pluronic® F-127, Sigma) was added to each well. The plates were incubated at 37°C for 1 hour (exposure to light was avoided). For the FLIPR assay, the excitation wavelength was set to 470 / 495 nm and the emission wavelength to 515 / 575 nm (Molecular Devices). The assay was performed in both agonist and antagonist modes. In agonist mode, 10 μL of diluted compound was transferred to the cell culture wells and incubated at room temperature for 10 minutes. In antagonist mode, 10 μL of compound diluted with 8 nM acetylcholine (EC80, MedChemExpress) was added to each well and incubated at room temperature for 10 minutes. The RFU value was calculated by subtracting the minimum value from the maximum value of the FLIPR signal. The inhibitory effect of the compound on acetylcholine-induced calcium flow was given by % effect = (RFU サンプル -RFU DMSO ) / (RFU スコポラミン -RFU DMSO The calculation was performed using ) × 100. XLFit was used to fit the dose-response curve and IC of each compound. 50 The values ​​were calculated. The following table lists the IC50 values. * means IC50 > 1000nM, ** means 10 - 100nM, and *** < 10nM. JPEG2023550798000056.jpg76170

[0174] The summary and abstract sections may describe one or more exemplary embodiments of the invention, though not all, as intended by the inventors, and are therefore not intended in any way to limit the scope of the invention and the appended claims.

[0175] The present invention has been described above with the help of function building blocks that demonstrate the implementation of specific functions and their relationships. The boundaries of these function building blocks are arbitrarily defined herein for the sake of explanation. Different boundaries can be defined as long as the specific functions and their relationships are properly performed.

[0176] With respect to embodiments of the present invention described as a genus, all individual species are considered separately distinct embodiments of the present invention. Where an embodiment of the present invention is described as "including" a feature, the embodiment is also considered to "consist of" or "essentially consist of" that feature.

[0177] The foregoing description of specific embodiments sufficiently reveals the general nature of the invention, so others can readily modify and / or adapt such specific embodiments to various uses without unnecessary experimentation and without departing from the general concept of the invention, by applying knowledge within the scope of the art. Accordingly, such adaptations and modifications are intended to be within the meaning and scope of equivalents of the disclosed embodiments based on the teachings and guidance presented herein. It should be understood that the expressions or terms herein are for illustrative purposes only, and not limiting, so that the terms or expressions herein may be interpreted by those skilled in the art in light of the teachings and guidance.

[0178] The breadth and scope of the present invention should not be limited by any of the exemplary embodiments described above.

[0179] All of the various embodiments, configurations, and options described herein can be combined in any variation.

[0180] All publications, patents, and patent applications referenced herein are incorporated by reference to the same extent as individual publications, patents, or patent applications are specifically and individually indicated to be incorporated by reference. If any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in any document incorporated by reference, the meaning or definition assigned to that term in this document shall prevail.

Claims

1. A salt having the formula I, In the formula, X - is the counter ion, R 1 is hydrogen, L 1 Is, Sky, C 1-4 Alkylene, or C 1-4 is heteroalkylene, R 2 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 carbocyclyl, 4- to 8-membered heterocyclyl, phenyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted; R 3 and R 4 are each independently hydrogen or C 1-6 is alkyl, A salt characterized in that j is 0, 1 or 2.

2. The salt according to claim 1, characterized in that it has a formula according to formula I-1 or formula I-2.

3. L 1 is CH 2 The salt according to claim 1, characterized in that

4. L 1 is CH 2 3. The salt according to claim 2, wherein

5. R 2 teeth, (i) F, OH, R A , OR A C optionally substituted with one or more substituents independently selected from phenyl, 1-6 Alkyl, phenyl is halogen (e.g., F or Cl), OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4and R at each occurrence is optionally substituted with one or more substituents independently selected from alkoxy. A are independently F, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C optionally substituted with one or more substituents independently selected from alkoxy 1-4 Alkyl or C 3-6 Cycloalkyl C 1-6 Alkyl; (ii) C of the branch 3-6 Alkyl; (iii) F, OH, R A , and OR A C, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more substituents independently selected from 3-6 Cycloalkyl, and R at each occurrence A are independently F, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C optionally substituted with one or more substituents independently selected from alkoxy 1-4 Alkyl or C 3-6 Cycloalkyl C 3-6 Cycloalkyl; (iv) F, OH, R A , and OR A C, such as cyclopentenyl, optionally substituted with one or more substituents independently selected from 4-7 Cycloalkenyl, where R A are independently F, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 C optionally substituted with one or more substituents independently selected from alkoxy 1-4 Alkyl or C 3-6Cycloalkyl C 4-7 Cycloalkenyl; (v) F, Cl, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 phenyl optionally substituted with one or more substituents independently selected from alkoxy; (vi) 5-membered heteroaryl having 1 to 3 ring heteroatoms independently selected from N, O, and S, such as oxazolyl and thiazolyl, and further including F, Cl, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 a 5-membered heteroaryl optionally substituted with one or more substituents independently selected from alkoxy; or (vii) Heteroaryl having 6 members and 1 to 2 ring heteroatoms independently selected from N, O, and S, such as pyridyl or pyrimidinyl, and not including F, Cl, OH, C 1-4 Alkyl, fluorine-substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluorine-substituted C 1-4 The salt according to any one of claims 1 to 4, which is a 6-membered heteroaryl optionally substituted with one or more substituents independently selected from alkoxy.

6. R 3 The salt according to any one of claims 1 to 4, characterized in that: is methyl.

7. R 4 The salt according to any one of claims 1 to 4, characterized in that: is methyl.

8. The salt according to any one of claims 1 to 4, characterized in that j is 1.

9. X -The salt according to any one of claims 1 to 4, characterized in that: is a pharma- ceutically acceptable counterion.

10. A salt selected from those shown in Table 1 or 2, - is a pharma- ceutically acceptable counterion. Table 1 Table 2

11. A pharmaceutical composition comprising the salt according to any one of claims 1 to 10, and optionally a pharma- ceutically acceptable carrier.

12. 11. A method for treating hyperhidrosis, reducing drooling, reducing gastric or airway secretions, protecting the heart and nervous system, treating chronic obstructive pulmonary disease, inducing pupil dilation, and treating abdominal pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a salt according to any one of claims 1 to 10.

13. The method described in claim 12, characterized in that the method is used to treat hyperhidrosis and the administration is topical administration.

14. 1. A compound having formula II or a salt thereof: In the formula, R 1 is hydrogen, L 1 Is, Sky, C 1-4 Alkylene, or C 1-4 is heteroalkylene, R 2 is hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 carbocyclyl, 4- to 8-membered heterocyclyl, phenyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted; R 3 is hydrogen or C 1-6 is alkyl, A compound or a salt thereof, wherein j is 0, 1 or 2.